THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

61st Annual Meeting

THE RITZ-CARLTON®
AMELIA ISLAND

November 10-13, 1999

Jointly Sponsored by the American Association of Neurological Surgeons

THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

61st Annual Meeting

THE RITZ-CARLTON®
AMELIA ISLAND

November 10-13, 1999

Jointly Sponsored by the American Association of Neurological Surgeons

1999 OFFICERS AND COMMITTEES

PRESIDENT
J. Charles Rich

PRESIDENT ELECT
George A. Ojemann

VICE PRESIDENT
Donald O. Quest

SECRETARY
David G. Piepgras

TREASURER
L.N. (Nick) Hopkins

EXECUTIVE COMMITTEE
J. Charles Rich
George A. Ojemann
Donald O. Quest
David G. Peipgras
L.N. (Nick) Hopkins
Edward S. Connolly
Bryce K. Weir
Arthur L. Day
Bryon C. Pevenhouse

HISTORIAN
Byron C. Pevehouse

ACADEMY COMMITTEES 1999

ACADEMY AWARD COMMITTEE:

Kim J. Burchiel, (Chair)

Robert Ratcheson

R. Michael Scott

AUDITING COMMITTEE:

Martin Camins

Christopher Loftus

Paul Nelson

FUTURE MEETING SITES COMMITTEE

Martin Camins, (Chair)

Arthur L. Day

David G. Piepgras

MEMBERSHIP ADVISORY COMMITTEE

Julian Hoff, Chair

Edward S. Connolly

J. Charles Rich

David G. Piepgras

L. N. (Nick) Hopkins

Bryce K. Weir

Donald Quest

Ralph G. Dacey, Jr.

SUBCOMMITTEE ON CORRESPONDING MEMBERSHIP:

Edward R. Laws, Jr., (Chair)

Ralph Dacey, Jr.

Michael Apuzzo

NOMINATING COMMITTEE:

Edward S. Connolly

J. Charles Rich

George Ojemann

SCIENTIFIC PROGRAM COMMITTEE:

William Chandler, (Chair)

Howard Eisenberg

Robert Spetzler

ROUND ROBIN EDITOR:

David G. Piepgras

LOCAL ARRANGEMENTS:

Arthur L. Day

AANS JOINT SPONSORSHIP EDUCATION REPRESENTATIVE:

Richard Morawetz

GENERAL INFORMATION

REGISTRATION

Meeting Registration will be located in the foyer area of Salon III in the Ritz-Carlton.

REGISTRATION HOURS ARE:

Wednesday, November 10	3:00 PM – 9:00 PM
Thursday, November 11	7:00 AM – 5:00 PM
Friday, November 12	7:00 AM – 5:00 PM
Saturday, November 13	7:00 AM – 1:00 PM

SLIDE PREVIEW ROOM

The Slide Preview Room is located in the Boardroom and will be open during official registration hours.

MESSAGE CENTER

A telephone Message Center will be available in the Registration Area from Wednesday, November 10th through Saturday, November 13th during official registration hours. The message center has been assigned the following number: 904/277-1039

PROGRAM SUMMARY

Tuesday, November 9

12:00 Noon	ABNS Primary Exam Committee—*Kings Bay*
7:00 PM – 9:00 PM	ABNS Dinner—*Amelia Room*

Wednesday, November 10

7:00 AM – 8:00 AM	ABNS Breakfast—*Kings Bay*
8:00 AM – 4:00 PM	ABNS Primary Exam Committee—*Kings Bay*
12:00 PM – 1:00 PM	ABNS Luncheon—*Kings Bay*
2:00 PM – 3:00 PM	American Academy Executive Committee Meeting—*The Ambassador*
3:00 PM – 5:00 PM	American Academy Membership Committee—*The Ambassador*
3:00 PM – 9:00 PM	Registration—*Salon III Foyer*
4:00 PM – 9:00 PM	Speaker Ready Room—*The Boardroom*
6:30 PM – 10:00 PM	Welcome Reception—*Oceanfront Lawn*
7:30 PM – 10:00 PM	American Academy Executive Dinner—*The Amelia Room*

Thursday, November 11

7:00 AM – 5:00 PM	Registration—*Salon III Foyer*
7:00 AM – 5:00 PM	Speaker Ready Room—*The Boardroom*
7:00 AM – 9:00 AM	Buffet Breakfast (Spouses and Guests)—*The Talbot Room*
7:00 AM – 8:00 AM	Buffet Breakfast and Meeting (Members)—*Salon II*
8:00 AM – 1:00 PM	Scientific Session I—*Salon III*
9:54 AM – 10:15 AM	Coffee Break—*Salon III Foyer*

1:00 PM – 2:30 PM	ABNS Advisory Council Luncheon—*The Ambassador*
1:00 PM	Golf—*The Golf Club of Amelia Island*
3:00 PM	Tennis—*Ritz-Carlton Tennis Courts*
3:00 PM – 5:00 PM	Journal of Neurosurgery Meeting—*Director's Room*
6:30 PM – 7:00 PM	Reception—*Walkers Landing*
7:00 PM – 8:30 PM	Dinner—*Walkers Landing*

Friday, November 12

7:00 AM – 5:00 PM	Registration—*Salon III Foyer*
7:00 AM – 5:00 PM	Speaker Ready Room—*The Boardroom*
7:00 AM – 9:00 AM	Buffet Breakfast (Spouses and Guests)—*The Talbot Room*
7:00 AM – 8:00 AM	Buffet Breakfast and Meeting (Members)—*Salon II*
8:00 AM – 1:00 PM	Scientific Session II—*Salon III*
10:02 AM – 10:22 AM	Coffee Break—*Salon III Foyer*
11:55 PM – 12:30 PM	***Presidential Address:*** J. Charles Rich Introduction by: Donald O. Quest —*Salon III*
1:00 PM	Golf—*The Golf Club of Amelia Island*
3:00 PM	Tennis—*Ritz-Carlton Tennis Courts*
6:30 PM – 7:30 PM	Cocktails—*Ballroom Foyer*
7:30 PM – 10:30 PM	Black-tie Reception—*Salon II*

Saturday, November 13

7:00 AM – 5:00 PM	Registration—*Salon III Foyer*
7:00 AM – 5:00 PM	Speaker Ready Room—*The Boardroom*
7:00 AM – 9:00 AM	Buffet Breakfast (Spouses)—*The Talbot Room*
7:00 AM – 8:00 AM	Buffet Breakfast and Meeting (Members and Guests)—*Salon II*
8:00 AM – 1:00 PM	Scientific Session III—*Salon III*
10:02 AM – 10:22 AM	Coffee Break—*Salon III Foyer*
	1:00 PM Meeting Adjourns

SCHEDULE OF ACTIVITES FOR SPOUSES

The spouses of the American Academy members and guests are welcome to all events.

Wednesday, November 10

6:30 PM – 10:00 PM	Welcome Reception—*Oceanfront Lawn*

Thursday, November 11

7:00 AM – 9:00 AM	Buffet Breakfast—*The Talbot Room*
7:00 AM – 3:00 PM	Hospitality Suite—*The Talbot Room*
1:00 PM	Golf & Tennis
6:30 PM – 7:00 PM	Reception—*Walkers Landing*
7:00 PM – 8:30 PM	Dinner—*Walkers Landing*

Friday, November 12

7:00 AM – 9:00 AM	Buffet Breakfast —*The Talbot Room*
7:00 AM – 3:00 PM	Hospitality Suite—*The Talbot Room*
11:55 PM – 12:30 PM	Presidential Address: J. Charles Rich Introduction by: Donald O. Quest— *Salon III*
1:00 PM	Golf, Tennis, Shopping, Touring, etc.
6:30 PM – 7:30 PM	Cocktails—*Ballroom Foyer*
7:30 PM – 10:30 PM	Black-tie Reception—*Salon II*

Saturday, November 13

7:00 AM – 9:00 AM	Buffet Breakfast (Spouses)— *The Talbot Room*
7:00 AM – 3:00 PM	Hospitality Suite—*The Talbot Room*
1:00 PM	Meeting Adjourns

SCIENTIFIC PROGRAM
AMERICAN ACADEMY
OF
NEUROLOGICAL SURGERY
1999 LEARNING OBJECTIVES

Jointly Sponsored by The American Academy of Neurological Surgery November 10-13, 1999.

Following the Scientific Sessions, the participants will be able to: Critique the value of the recommended surgical and non-surgical options presented in the scientific papers.

Evaluate the relevance of the research methodologies, the findings, and the potential usefulness in practice of the topics presented for cerebrovascular, neoplastic, spinal and developmental and functional nervous system diseases.

The American Association of Neurological Surgery is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education of physicians.

The American Association of Neurological Surgery designated this continuing medical education activity for 14.25 credit hours in Category 1 of the American Medical Association.

SCIENTIFIC PROGRAM
AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

Thursday, November 11 Moderator—William Chandler, MD

8:00 AM-9:00 AM	Point-Counter-Point - Treatment of an unruptured 8 mm Aneurysm. Robert Spetzler, L. Nick Hopkins, David G. Piepgras
9:00 AM-9:18 AM	Posterior circulation aneurysms: results using combined surgical and endovascular techniques Christopher S. Ogilvy, Christopher Putman, Ronald Budzik, Alex Norbash, In Sup Choi
9:18 AM-9:36 AM	Surgical repair of endovascularly untreatable trasitional cavernous carotid aneurysms Fredric B. Meyer, Jonathan A. Friedman, Douglas A. Nichols
9:36 AM-9:54 AM	Retrospective analysis of carotid revascularization at the Univ. of Buffalo, Department of Neurosurgery Lee R. Guterman, James L. Budny, L. Nick Hopkins
9:54 AM-10:15 AM	Coffee
10:15 AM-10:33 AM	Unilateral acoustic tumors in younger individuals with out neurofibromatosis Jon H. Robertson, Gale Gardner, John J. Shea
10:33 AM-10:51 AM	Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma Keith L.Black, Christopher Wheeler, Paul Zeltzer, Divina Nacis, Paul Lee, John S. Yu

10:51 AM-11:09 AM	Tumor control and reversal of cranial nerve deficits after focused radiation therapy for intracavernous meningiomas John M. Tew, Abhay Sanan, Rashid M. Janjua, Harry R. Van Loveren, John C. Breneman
11:09 AM-11:27 AM	The contemporary surgical management of Chiari I malformation in children Mark D. Krieger, Michael L. Levy, J. Gordon McComb
11:27 AM-11:45 AM	Emergency decompression for cervical spinal cord injury: improved outcome and reduced cost Stephen M.Papadopoulos, Nathan R. Selden, Nayna Patel, Brenda Gillespie, Douglas J. Quint, Susan Grube
11:45 AM- 12:03 PM	Effect of timing of decompression on neurological outcome following spinal cord injury Christopher B. Shields, John R. Dimar, George H. Raque, Y. Ping Zhang, Steven D. Glassman
12:03 PM-12:21 PM	Controlled cortical impact injury to reat brain up-reglates peripheral-type benzodiazapine receptor expression in the thalamus Robert J. Dempsey, V. L. Raghavendra Rao, A. Dogan, K. K. Bowen
12:21 PM-12:41 PM	***Academy Award Paper.*** Reduction of post-traumatic spinal cord injury by inhibition of the caspase cascade Robert Friedlander, M. Li, V. O. Chen, M. Kaul, L. Tenneti, Phillip Stieg, S.A. Lipton
12:41 PM-1:00 PM	***Academy Award Paper- Runner up.*** Fas upregulation in high-grade gliomas results in increasd apoptosis and survival Bruce Frankel, Timothy Ryken, Sharon Longo, Michele Kyle

Friday, November 12	**Moderator—Howard Eisenberg, MD**
8:00 AM-8:50 AM	Point-Counter-Point - To plate or not to plate in a single level anterior discectomy Volker Sonntag, Stephen Papadopoulos
8:50 AM-9:08 AM	Surgical experience with an artificial cervical joint James T. Robertson, S. Gill, R. Nelson, N. Metcalf
9:08 AM-9:26 AM	Outcome of 51 cases of unilateral locked cervical facets: interspinous braided cable for lateral mass plate fusion compared with interspinous wire and facet wiring with iliac crest J. Kevin Kaufman, Scott A. Shapiro, Paul B.Nelson
9:26 AM-9:44 AM	Image guidance in spinal surgery: an update Gerald Rodts, Kevin Foley
9:44 AM- 10:02 AM	Developing new technology: An accurate laser targeting system for fluoroscopically assisted procedures Michael K. Landi
10:02 AM-10:22 PM	**COFFEE**
10:22 AM-10:40 AM	Outcomes studies in carotid endarterectomy Robert E. Harbaugh
10:40 AM-10:58 AM	Improved management of childhood medulloblastoma using proton beam radiotherapy Paul H. Chapman, Nancy J. Tarbell, William E. Butler, Jay S. Loeffler
10:58 AM–11:16 AM	Radical resection of gliomas in functioning brain regions utilizing awake cortical and subcortical mapping and frameless stereotaxis Fredric B. Meyer, Lisa M. Bates, Stephen J. Goerss, Wanda L. Windschitl, Jonathan A. Friedman

11:16 AM-11:34 AM	FasL expression in tumor vessels of patients with glioblastoma multiforme John S. Yu, Yun-hui Liu, Chunren Liu, Ken Samoto, Moneeb Ehtasham, Keith L. Black
11:34 AM- 11:52 AM	Stereotactic radiosurgery: the treatment of choice for jugular foramen region tumors? Bruce E. Pollock, Deborah A. Gorman
11:55 AM- 12:30 PM	***Presidential Address:*** Athletic Performance Enhancement: The Difference between Sports Science and Sports Medicine **J. Charles Rich**

Saturday, November 13	**Moderator: Robert Spetzler, MD**
8:00 AM-8:50 AM	Point-Counter-Point - Aggressive resection versus biopsy of a low gradeglioma Mitchell L. Berger, L. Dade Lunsford
8:50 AM-9:08 AM	Results of a phase I study of the treatment of malignant gliomas with the genetically-engineered herpes simplex virus G207 James A. Markert, Michael D. Medlock, Samuel Rabkin, Yancey Gillespie, Frank Feigenbaum, William D. Hunter, Tomoki Todo, Carlo Tornatore, Robert L. Martuza
9:08 AM-9:26 AM	Clinical and economic consequences of early discharge after stereotactic brain biopsy Gene H. Barnett, Wayel Kaakaji, Diane Bernhard, Kren Valaitis, Sarah Stamp, Narongsak Boonswag
9:26 AM- 9:44 AM	An ideal syngeneic mouse glioma for testing immunotherapy strategies Warnick RE, Weiner NE, Pyles RB, Chalk CL, Balko GO, Miller MA, Dyer CA, Parysek LM

9:44 AM-10:02 AM	Intraoperative human sensorimotor and language mapping using optical intrinsic signal imaging: comparison with electophysiologic techniques and fMRI in 40 patients Neil Martin, Andrew Cannestra, Nader Pouratian, Donald Becker, Susan Bookheimer, Nancy Sicotte, Arthur Toga
10:02 AM-10:22 AM	COFFEE
10:22 AM-10:40 AM	New neurosurgical perspectives on spontaneous intracerebral hemorrhage Issam A. Awad
10:40 AM-10:58 AM	3-D computer modeling of the cerebral vasculature Paul S. Larson, Chuck Sites, Ashraf Mohamed, Ayman M. Eldeib, Todd Vitaz, Aly A. Faraq, Thomnas M. Moriarty, Christopher B. Shields
10:58 AM-11:16 AM	Instrumentated fusion in the management of post-laminectomy lumbar stenosis Charles L. Branch, David Jones
11:16 AM-11:34 AM	Early moderate hyperventilation does not reduce cerebral metabolism following severe traumatic brain injury Robert L Grubb, Thomas Videen, Allyson R. Zazulia, Ellen Deibert, Venkadesh Aiyagari, Ralph G. Dacey, Michael N. Diringer, William J. Powers
11:34 AM-11:52 AM	Intracranial hypertension and cerebral perfusion pressure: their influences on neurological deterioration and outcome in severe head injury N. Juul, G.F. Morris, S. B. Marshall, The Executive Committee of the International Selfotel Trial, L. F. Marshall

Saturday, November 13

11:52 AM-12:10 PM	Flourescence-guided surgery of malignant gliomas utilizing 5-ALA-induced porphyrins. Experience with 66 consecutive patients. H.J. Reulen, R. Baumgartner, W. Stummer
12:10 PM-12:28 PM	Genetically engineered cytotoxic T lymphocytes targeted against angiogenesis: A novel anti-glioma strategy Zoher Ghogawala, Robert Carter, Thomas Niederman, Richard C. Mulligan
12:28 PM-12:46 PM	Elevation of the internal auditory canal pressure by vestibular schwannomas Behnam Badie, Mark Pyle, Peter Nguyen

NOTES:

THURSDAY, NOVEMBER 11 9:00-9:18 AM

Posterior Circulation Aneurysms: Results Using Combined Surgical and Endovascular Techniques

Christopher S. Ogilvy, Christopher Putman, Ronald Budzik, Alex Norbash, In Sup Choi

Massachusetts General Hospital, Harvard Medical School, Boston, MA

Posterior circulation aneurysms can be difficult to treat depending upon the exact anatomic relation to the bony architecture, size, patient's neurologic condition, age, and presence or absence of subarachnoid hemorrhage. In an effort to improve outcome, we have utilized both surgical and endovascular (GD coil therapy) techniques over the past 9 years. As each patient was encountered, surgery was considered the primary mode of therapy. If the surgical risk was estimated to be high, an endovascular strategy was utilized.

We reviewed 199 patients with posterior circulation aneurysms treated over a 9 year interval (1990-1998) at the Massachusetts General Hospital. Of these, 139 patients were treated with surgery and 60 with endovascular techniques. Patients were graded using a previously described system (MGH grade) which incorporates age, clinical condition (Hunt & Hess grade), size of lesion, and density of SAH. Patients in poor neurologic condition were managed aggressively if brainstem function was present. Using this approach, distribution of treatment was as follows: PICA: 21 surgical, 8 GDC; AICA: 3 surgical, 4 GDC; VB junction: 3 surgical, 14 GDC; basilar trunk: 5 surgical, 2 GDC; SCA: 27 surgical, 4 GDC; PCA: 7 surgical, 6 GDC; basilar tip: 73 surgical, 22 GDC.

Overall clinical outcome was evaluated by a nurse practitioner. Followup ranged from 6 months to 8.5 years. Results were excellent/good in 154 patients (77% of total), fair in 16 patients (8%), poor in 8 patients (4%), and fatal in 21 patients (11%). Of these fatalities, 12 were in the endovascular group (7 from hemorrhage or rehemorrhage) and 9 were in the surgical group (1 from rehemorrhage). As endovascular techniques continue to evolve, a careful case-by-case analysis should be utilized to determine the mode of therapy (surgical vs. endovascular) to best improve overall outcome.

Surgical Repair of Endovascularly Untreatable Transitional Cavernous Carotid Aneurysms

Fredric B. Meyer, M.D., Jonathan A. Friedman, M.D.,
Douglas A. Nichols, M.D.

Aneurysms of the carotid artery that originate in the cavernous sinus or extracavernous, extradural segment but extend through the distal dural ring into the subarachnoid space are termed ìtransitionalî carotid aneurysms. The surgical treatment of these lesions is often difficult because of their complex anatomy. In many circumstances endovascular techniques are the treatment of choice. Analyzed here are the techniques and results in 42 transitional aneurysms not suitable for interventional techniques: wide neck 5 mm, incorporation of the ophthalmic, Acho, PoCom into the aneurysm neck, failure of trial balloon occlusion. There were 39 females and 3 males with an average age of 55. Fifteen patients had bilateral cavernous aneurysms, 5 of whom underwent bilateral craniotomies. Twenty-seven aneurysms were 10-15 mm, nine were 15-25 mm, and six were >25 mm in size. The most common presentation was mass effect including visual loss. Five presented with subarachnoid hemorrhage. Thirty-nine had direct clipping, two had trapping with bypass, and one had trapping alone. The complication rate was 12% consisting of 1 death in a H+H grade 4 patient, 1 major stroke, 2 minor strokes, and 1†treated brain abscess. Based on this experience the following recommendations are made to facilitate management of transitional carotid aneurysms not treatable with contemporary endovascular techniques: 1) CT scan to identify neck calcification, 2) detailed angiogram including ìaneurysmgram,î 3) trial balloon occlusion with CBF studies, 4) radiolucent headholder and exposure of cervical carotid artery for proximal control and planned intraoperative angiogram, 5) extradural removal of sphenoid wing and anterior clinoid, 6) †availability of intraoperative doppler flow or CBF measurements.

THURSDAY, NOVEMBER 11 9:36-9:54 AM

Retrospective Analysis of Carotid Revascularization at the University of Buffalo, Department of Neurosurgery May 1, 1995 — July 1, 1998

Lee R. Guterman PhD MD, James L. Budny MD, and L. N. Hopkins MD

Purpose:

To compare carotid endarterectomy (CEA) to carotid angioplasty and stent as a method for carotid revascularization in 228 consecutive patients who presented to the neurosurgery service study.

- **Retrospective chart**
- **Angiographic film review**

Primary Endpoints

- **Major stroke 30 d**
- **Death 30 d**
- **MI 30 d**

Secondary Endpoints

- **Minor Stroke 30d**
- **TIA 30d**

Goals

Compare medical comorbidity in each population to quantify the overall state of health for this population. Prior to this review it was assumed patients in the stent group had a higher morbidity index than the CEA group.

Abstract

There were 228 patients treated at Millard Fillmore Hospital between May 1, 1995 and July 1, 1999 who presented with cervical carotid bifurcation disease. There were 94 patients revascularized using carotid angioplasty followed by stent placement and 134 revascularized using endarterectomy. The group was predominantly male (61.4%) with an average age of 69 years. In the stent group 71.3% were male. The majority of patients were Caucasian (88% stent, 97% CEA).

CEA was performed under general anesthesia with EEG monitoring. Pharmacologic burst suppression was used in the majority of these cases.

Angioplasty and stent was performed on awake patients using intravenous sedation.

Comorbid medical conditions were documented and stratified within each group. Diabetes, pulmonary disease, asthma, CCS class, NYSHA class, angina, renal disease, neurologic disease, ejection fraction, arrhythmias, malignancy, surgical hx, smoking hx, coagulation hx, and medications were among 145 variables monitored for each procedure. Angiograms were analyzed in 88 stent patients and 103 endarterectomy patients.

Unstable angina requiring IV nitrates for control was encountered in 16% of stent patients and 0.7 % of CEA patients. CCS class was III/IV in 23.4% of stent patients and 4.4% of CEA patients. Seven patients (7.4%) in the stent group and 1 patient (0.7%) presented after CEA at another institution resulted in stroke. Restenosis was seen in 22 patients (23.4%) in the stent group and 4 patients (3.0%) in the CEA group. Ejection fraction was 40% or less in 12.8 of stent patients and 3.0% of CEA patients. NYSA class III patients 21.3% stent 5.2% CEA while class IV patients 9.6 stent and 0% CEA.

Four patients (4.3%) in the stent group had malignancies while 18 patients (13.4%) in the CEA group were afflicted. These were skin and soft tissue lesions.

Smoking history was essentially equivalent in the two groups. ICU admission within six months prior to surgery was seen in 13.8% of stent patients and 6.7% of the CEA patients.

Contralateral carotid occlusions were present in 23% of the stent population and 9.3% of the CEA population. Carotid string sign was present in 5.7% of stent patients and no CEA patients.

Procedural Complications

Transient ischemic attacks resulted in 1 patient (1.1%) in the stent group and 2 patients (1.5%) in the CEA group. There were 7 procedural related transient events in the stent group (7.4%) and one in the CEA group. There were 3 minor strokes in the stent group (3.2%) and 2 (1.5%) in the CEA group. Neither group had a major stroke. There was one MI in the stent group (1.1%) and 2 in the CEA group (1.5-%). In the stent group there were 4 pseudoaneurysms of the femoral artery and three of these required surgical exploration and repair. There was 1 wound infection in each group.

THURSDAY, NOVEMBER 11 10:15-10:33 AM

Unilateral Acoustic Tumors in Younger Individuals Without Neurofibromatosis

Jon H. Robertson, M.D., Gale Gardner, M.D., John J. Shea, III, M.D.

Objective: The purpose of this presentation will be to identify the unique characteristics of acoustic tumors presented in a population group of young individuals (less than 35 years of age) and the results of surgical management of these patients.

Methods: A retrospective chart review of 420 patients who underwent surgery for removal of an acoustic tumor by the senior author during an eighteen year period (1981-1999) was completed. 12% (N=52) of these patients were found to be younger than 35 years of age. Patients with neurofibromatosis were excluded from the study. The selected group of patients included 28 males and 24 females. Analysis of this subgroup of younger patients with acoustic tumors was directed to their clinical presentation, tumor size, histological features and surgical outcome.

Conclusion: Younger individuals with acoustic tumors tend to have larger tumors with a shorter duration of symptoms. Larger tumors of all age groups tend to be more vascular. This study will emphasize the technical difficulties encountered in this selected group of patients with large acoustic tumors and the outcome of facial nerve preservation.

Dendritic Cell Immunotherapy for Patients with Glioblastoma Multiforme and Anaplastic Astrocytoma

Keith L. Black, Christopher Wheeler, Paul Zeltzer, Divina Nacis, Paul Lee, John S. Yu

This Phase I Study was initiated to assess the safety of an immunotherapy trial using peripheral blood dendritic cells to present brain tumor-specific markers to the patient's immune system. Dendritic cells are an extremely small subset of a person's white blood cell population that are exclusively involved in presenting foreign antigens to the body's immune system. Patients in the study with either glioblastoma or anaplastic astrocytoma have undergone phlebotomy or leukapheresis, a method of removing a large number of white cells from the blood. These cells were made into dendritic cells with ex vivo treatment with interleukin 4 and GM-CSF. The patient, after having their tumor removed at surgery, had their tumors grown and tumor antigens eluted. The tumor antigens were then mixed with dendritic cells and then reinjected subcutaneously back into the patient. The goal of this protocol was to reactivate the patientís immune system to recognize and kill remaining tumor cells which have infiltrated the brain.

Fourteen patients have been treated with dendritic cell immunotherapy protocol. Eleven patients had glioblastoma multiforme, five patients had anaplastic astrocytoma. Eight patients were treated after first time diagnosis of their tumor and six patients with recurrent glioblastoma multiforme or anaplasticastrocytomaweretreated. Age ranged from 29-61 years. Two patients progressed during the time of the protocol and died during follow-up. No significant adverse events were noted. One patient had a transient fever with one episode of nausea and vomiting two days after treatment. One patient reported transient headache and the same patient developed significant axillary and inguinal lymph nodes after his second vaccination. Immunologic studies were performed on six patients so far. Four of the six patients developed significant cytotoxicity against brain tumor antigens established through the JAM cytoxic T-cell assay. This Phase I study shows that vaccination with dendritic cells pulsed with eluted MHC-I associated antigens is safe in the treatment of patients with newly diagnosed or recurrent glioblastoma multiforme and anaplastic astrocytoma. There appears to be significant induction of specific immunity in four out of six patients tested. Further monitoring is required to determine any future adverse events including any autoimmune phenomena.

THURSDAY, NOVEMBER 11 10:51-11:09 AM

Tumor Control and Reversal of Cranial Nerve Deficits After Focused Radiation Therapy for Intracavernous Meningiomas

John M. Tew, MD, Abhay Sanan, MD, Rashid M. Janjua, MD, Harry R. Van Loveren, MD, John C. Breneman, MD

The Neuroscience Institute: University of Cincinnati Department of Neurosurgery, Radiation Oncology, and the Mayfield Clinic

Introduction: Appropriate treatment of meningiomas involving the cavernous sinus remains controversial. Direct microsurgical attack on intracavernous meningiomas carries substantial morbidity. Consideration of focused radiation therapy to treat meningiomas of the cavernous sinus raises questions regarding the radiation tolerance of cranial nerves and the ability of radiation to control tumor size. We have adopted a conservative strategy for intracavernous meningiomas, reserving treatment (whether surgery or radiation) for patients whose meningiomas grow and produce increasing symptoms.

Objective: Because of our concern that focused radiation therapy may further injure cranial nerves already compromised by infiltrating tumor, we undertook this study to assess the cranial nerve morbidity of radiation treatment and the ability of radiation to control tumor size.

Methods: All intracavernous meningiomas treated with focused radiation therapy (3-D conformal or stereotactic) at the University of Cincinnati were retrospectively reviewed. Patients who received postoperative radiation were excluded.

Results: Eighteen patients were identified with intracavernous meningiomas that received focused radiation therapy, 11 of whom (our study group) received focused radiation therapy as their initial treatment (vs. a postoperative adjunct). Six patients received stereotactic radiosurgery (mean 1550 cGy) and 5 received 3-D conformal therapy (mean 4932 cGy). Cranial nerve deficits improved in 3, remained unchanged in 7, and worsened in 1. Tumor size was controlled in 11 (100%) patients (mean follow-up 18 months).

Conclusions: Focused radiation therapy can achieve excellent control of intracavernous meningiomas. Cranial nerves of the cavernous sinus seem relatively resistant to injury with the radiation doses used; often preoperative deficits resolve. The short follow-up period limits the long-term predictive value of our conclusions.

The Contemporary Surgical Management of the Chiari I Malformation in Children

Mark D. Krieger, MD, Michael L. Levy, MD and J. Gordon McComb, MD

A wide variety of surgical adjuvants to the standard bony decompression have been advocated in the treatment of the Chiari I malformation, especially when the tonsillar herniation is associated with hydrosyringomyelia. Our practice has been to avoid such adjuvants as duroplasty, obex plugging, cerebellar tonsil resection, and various shunting procedures, and to perform a simple limited occipital craniectomy (<2.5cm in diameter), C1 laminectomy, and dural opening. To evaluate the efficacy of this more limited procedure, a retrospective review was performed of the medical records of 52 consecutive patients treated surgically over a 6-year period. This series includes long-term follow-up of a prior series (4-8 years), as well as 21 additional patients treated in a standard fashion. Included are 27 females and 25 males, ranging in age from 3 months to 18 years (median 11.5 years). Of particular interest is the large number of patients discovered during evaluation for scoliosis (38 patients-73% of the total series), which partially accounts for the large number of patients who harbored a syrinx (44-85%) in this series. All patients had at least one postoperative MRI at 6 months. Syrinx resolution or >50% diminution was seen in 89%. 48 of the patients responded well; 4 patients required subsequent operative procedures: 2 developed progressive hydrocephalus and required ventriculoperitoneal shunting, with symptom resolution. In the other 2 patients the syrinx did not diminish; both received syringopleural shunts. Importantly, no patient who responded satisfactorily at 6 month follow-up subsequently failed either radiographically or clinically. Postoperative morbidity consisted of a 21% incidence of headaches, all of which except 2 resolved within 7 days. Nausea and vomiting occurred in 13%. Four patients did have a postoperative CSF leak; all responded to bedside suturing without further sequelae. This study demonstrates the importance of addressing the Chiari I malformation, especially in the presence of scoliosis with a syrinx, and the effectiveness of a limited surgical approach.

Emergency Decompression for Cervical Spinal Cord Injury: Improved Outcome and Reduced Cost

Stephen M. Papadopoulos, M.D., Nathan R. Selden, M.D., Ph.D., Nayna Patel, B.A., Brenda Gillespie, Ph.D., Douglas J. Quint, M.D., Susan Grube, R.N.

Immediate pharmacological treatment of acute spinal cord injury has improved neurological outcome in experimental animal models and in clinical trials. The effect of immediate surgical spinal cord decompression on neurological outcome after injury, however, is controversial. Experimental models strongly suggest a beneficial effect of early decompression but there is little supportive clinical evidence.

In order to address this issue, ninety-one consecutive patients with acute, traumatic cervical spinal cord injury (1990-1997) that initially received conventional emergency treatment with cervical immobilization and corticosteroids were prospectively studied. Sixty-six patients (protocol group) underwent emergency magnetic resonance imaging to determine the presence of persistent spinal cord compression followed if indicated, by immediate operative decompression and stabilization. Twenty-five patients were managed outside the protocol because of contraindication to magnetic resonance imaging, need for other emergency surgical procedure, or admitting surgeon preference (reference group). The protocol and reference groups had similar sex and age distributions, admitting Frankel grades, levels of neurological injury, and injury severity scores.

Protocol patients improved an average of 0.7 Frankel grades more than reference patients between admission and most recent follow-up ($p < .01$). Fifty percent of protocol patients, compared to only 24% of reference patients improved from their admitting Frankel grade. Eight protocol patients (12%), but no reference patients, improved from complete motor quadriplegia (Frankel grade A or B) to independent ambulation (Frankel grade D or E). Protocol patients required significantly fewer days of ventilatory support, shorter intensive care unit stays, and shorter total hospital stays than reference patients, representing an average savings per case of approximately $50,200 in 1997 hospital charges.

We conclude that immediate magnetic resonance imaging to determine the need for emergency operative decompression and stabilization significantly improves neurological outcome and reduces cost in the management of acute traumatic cervical spinal cord injury.

Effect of Timing of Decompression on Neurological Outcome Following Spinal Cord Injury (SCI)

Christopher B. Shields, MD, John R. Dimar, MD, George H. Raque, MD, Y. Ping Zhang, MD, Steven D. Glassman, MD

Optimal timing of decompression of the spinal cord (SC) following SCI with concomitant spinal stenosis (SS) remains controversial. Some surgeons recommend emergent decompression and others believe that timing of decompression has no effect on long term outcome. To answer this question we asked two critical questions: 1) what constitutes a significant spinal stenosis following SCI, and 2) what is the optimal timing of decompression following SCI + concomitant spinal stenosis? In an earlier experiment, we performed a T10 laminectomy in Spraque-Dawley rats and inserted different sized spacers at the level of moderate SCI (25 gm-cm created using a NYU impactor). We observed that narrowing of the spinal canal by a 35% sized spacer was the greatest degree of spinal stenosis that consistently showed neurological improvement ($p<0.05$). In this experiment, 42 Spraque-Dawley rats underwent a T10 laminectomy, a moderate SCI, and insertion of a 35% spacer which was left in the epidural space for 2, 6, 24, or 72 hours, then removed. All rats were evaluated weekly for 6 weeks using the BBB locomotor score. The neurological outcome was significantly greater the earlier that the decompression was performed. BBB scores for rats in which the decompression was performed at 2 hours was > than at 6 hours, > than at 24 hours, and > than at 72 hours ($p<0.05$). If extrapolated clinically, the greater the degree of spinal stenosis existing following a spinal cord injury, the poorer the neurological outcome. Furthermore, neurological outcome improve the earlier the spinal cord can be decompressed.

Controlled Cortical Impact Injury to Reat Brain Up-reglated Peripheral-type Benzodiazapine Receptor Expression in the Thalamus

Robert J. Dempsey, V.L. Raghavendra Roa, A. Dogan, K.K. Bowen

In mammalian CNS, the peripheral-type benzodiazepine receptor (PTBR) is localized on the outer mitochondrial membrane of astrocytes and microglia. PTBR transports cholesterol across mitochondrial membranes to the site of neurosteroid biosynthesis. Several neurodegenerative disorders were reported to be associated with increased PTBR density. In the present study, we evaluated the changes in the PTBR density and gene expression in the brains of rats as a function of time (6h to 14 days) after controlled cortical impact injury. Moderate grade injury was induced in adult, male, Sprague-Dawley rats under halothane anesthesia. Sham-operated rats served as control. Between 3 to 14 days after TBI, there was a significant increase in the binding of the PTBR antagonist [3H]PK11195 (by 106 to 185%, $p<0.01$; as assessed by quantitative autoradiography and in vitro filtration binding) and PTBR mRNA expression (by 2 to 3.4 fold, $p<0.01$; as assessed by RT-PCR) in the ipsilateral thalamus. At 14 days after the injury, the neuronal number decreased significantly (by 85 to 90%, $p<0.01$) in the ipsilateral thalamus. At the same time point, the ipsilateral thalamus also showed increased numbers of GFAP positive cells (reactive astrocytes; by ~3.5 fold) and the ED-1 positive cells (activated microglia/macrophages; by ~36 fold), the two cell types known to be associated with PTBR. Increased PTBR expression following brain injury is possibly an adaptive response to cellular injury and may play a role in the pathophysiology of TBI. Such studies explore the basic mechanisms of injury and repair after brain trauma and may result in future trails of gene therapy to enhance healing after traumatic brain injury. Supported by NIH, VA, AHA and the UW-Madison Medical School.

Academy Award Paper

Reduction of Post-traumatic Spinal Cord Injury by Inhibition of the Caspase Cascade

M. Li (1), V.O. Ona (1), M. Chen (1), M. Kaul (2), L. Tennti (2), P.E. Stieg (1), S. A Lipton, and R.M. Friedlander (1)

Evidence indicates that both necrotic and apostolic cell death contribute to tissue injury and neurological dysfunction following spinal cord injury (SCI). Caspases have been implicated as important mediators of apoptosis following acute central nervous system insults, We investigated whether caspase-1 and caspase-3 are involved in SCI-mediated cell death, and whether caspase inhibition may reduce tissue damage and improve outcome following SCI. We demonstrate a 17-fold increase in caspase-1 activity in traumatized spinal cord samples when compared to samples from sham operated mice. Caspase-I and caspase-3 activation was also detected by Western blot following SCI, which was significantly inhibited by the broad caspase inhibitor zVAD-fmk. By immunofluorescence or in situ fluorogenic substrate assay, caspase-1 and caspase-3 expression was detected in neuronal and non-neuronal cells following SCI zVAD-fmk treated mice, and transgenic mice expressing a caspase-I dominant negative mutant, demonstrated a significant improvement of motor function and a reduction of lesion size compared to vehicle-treated mice. Our results demonstrate for the first time that caspase-1 is activated following SCI, and that caspase inhibition reduces post-traumatic lesion size and improves motor performance. Caspase inhibition may be a strategy for the treatment of SCI.

Academy Award Paper-Runner up

Fas Upregulation in High-grade Gliomas Results in Increased Apoptosis and Survival

Bruce Frankel, M.D., Sharon L. Longo, B.S., Michele Kyle, B.A., and Timothy C. Ryken, MD

Although a majority of high-grade gliomas express Fas (APO- 1, CD95), a cell surface receptor that mediates apoptosis, when it reacts with Fas ligand (FasL) or Fas antibody, little is known about its effects on glioma viability in vivo. In this study, we used in situ labeling of DNA breaks to estimate the proportion of cells undergoing apoptosis in 51 high-grade human astrocytomas (18 WHO grade III and 33 grade IV tumors). A significant correlation between apoptotic index (AI), tumor grade and the degree of Fas expression was demonstrated. The mean AI significantly increased from .39% in grade III astrocytomas to .82 % grader IV tumors (p=0.003). In addition, high-grade astrocytomas, (grade III and IV combined) expressing high levels of Fas had a significantly greater AI than those expressing low levels of Fas (. 81 % vs. 43%)(p= 0.017).

Despite a trend toward longer median survival for patients with Tumors exhibiting high Fas expression, statistical significance was not achieved. Patients with grade III astrocytomas demonstrated a median survival of 20 months vs. 18 months for tumors with high vs. low Fas expression, respectively (p = .51). Patients with grade IV astrocytomas demonstrated a median survival of 9 months vs. 7.4 months for tumors with high vs. low Fas expression, respectively (p= .77). It was subsequently determined that the cell surface expression of Fas in several human glioblastoma (GBM) cell lines was low, explaining the limited susceptibility of these cells to

Fas-mediated cytotoxicity. Through the use of Fas receptor upregulation by gene transfer in a rat glioma cell line (36B 10), a correlation was demonstrated between increased Fas cell surface expression, and Fas-mediated apoptosis. In fact, the percent of cells undergoing apoptosis after exposure to a FasL producing cell line increased from 4% in a sham transfected line (36B10-) to 27% in a Fas transfected line (36BI0 Fas).

Finally, the effect of Fas upregulation on survival was studied in immune competent rats with intacranial malignant gliomas. Survival length was assessed after the implantation of 36BIO- and 36B10-Fas. The median survival increased significantly from 14 days (36B10-) to 24.5 days (3 6BIO-Fas), representing a 75% increase in survival in the higher Fas-expressing group ($p = .0005$). In conclusion, it appears that the overall low AI (range: 0-2.0%) seen in high-grade astrocytomas is related to low cell surface expression of Fas. By increasing surface Fas expression, rates of Fas-mediated apoptosis increase, as does survival.

NOTES:

NOTES:

NOTES:

FRIDAY, NOVEMBER 12 8:00-8:50 AM

Surgical Experience with an Artificial Cervical Joint

J. T. Robertson, S. Gill, R. Nelson, N. Metcalf

University of Tennessee, Memphis

847 Monroe, Suite 427

Memphis, Tennessee 38163

INTRODUCTION

After anterior cervical fusion, a two to three per cent incidence per year of adjacent disc disease occurs. With multiple levels of fusion, additional fusion limits neck motion. Maintenance of motion by a cervical joint may prevent adjacent disc disease and enhance motion.

AIM

To determine the clinical utility of an artificial stainless steel cervical joint placed in the intervertebral space after discectomy.

METHODS

After ethical committee approval at Frenchay Hospital, Bristol, England, a 15 patient pilot study was done in patients with radiculopathy and/or myelopathy due to disc disease at the level adjacent to previously acquired congenital or surgical fusion or for patients with a single level symptomatic disc with adjacent cervical disc degeneration. The patients underwent anterior radical discectomy and removal of the appropriate osteophytes with the implantation of the cervical joint. Visual analog scales for pain, neurological examinations, neck disability and SF36 scores pre operatively and at six week, three months, six month and one year visits were done.

RESULTS

All patients have maintained joint function as demonstrated by flexion/ extension cervical spine x-rays. All observational scores demonstrated significant improvement. There have been no neurological or wound complications.

SIGNIFICANCE AND CONCLUSIONS

This artificial stainless steel cervical joint placed in the intervertebral space after discectomy maintains motion segment function, has been without complication, and is effective in improving patient results. The ability to preserve motion by the joint is anticipated to reduce adjacent disc degeneration and to insure preservation of preoperative cervical motion.

Outcome of 51 Cases of Unilateral Locked, Cervical Facets; Interspinous Braided Cable for Lateral Mass Plate Fusion Compared with Interspinous Wire and Facet Wiring with Iliac Crest.

J.Kevin Kaufman, M.D., Scott A. Shapiro, M.D., Paul B. Nelson, M.D.

5 consecutive patients with unilateral looked facets of the cervical spine underwent treatment over an 11-year period. With the development of internal fixation devices, the authors compared the procedure of using interspinous wire and facet wiring of iliac crest to fix Linilateral locked facets with that in which interspinous braided cable and lateral mass plates were used. Thirty-seven patients (73%) presented with radiculopathy\ eight (16%) -with neck pain only, and six (12%) with spinal cord injuries (Sets). Plain x-ray films demonstrated subluxation in only 44 (86%) of 5 1 cases. All patients underwent cervical computerized tomography (CT) scanning, and in all patients with SCI, a magnetic resonance (MR) image was obtained. Fracture in addition to facet locking was seen on 24 (47%) of 51 CT scans. Disc disruption with cord compression was seen in five cases (10%). Based on CT and/or MR imaging findings, a closed reduction procedure was believed to be contraindicated in 11 cases (22%). Of the, remaining 40 patients, 13 (33%) underwent closed reduction procedures. Two patients who underwent a closed reduction procedure were placed in a halo brace but experienced resubluxation and were surgically treated. Forty-six patients underwent posterior reduction and/ or internal fixation alone (in 24 cases spinous process fixation with facet wiring and connected to struts of iliac crest, and in 22 cases interspinous braided cable for lateral mass plating was used).

Initial surgery, regardless of technique, was successful in 45 (98%) of 46 cases. One patient experienced a resubluxation and underwent reoperation in which anterior cervical fusion and plating were performed. Four of six patients with SO underwent an emergency combined anterior-posterior compressive procedure in which internal fixation was performed. Overall there were no cases of neurological worsening or death, and there were three cases of wound infection. At I year postsurgery, all deficits had improved. Of 37 cases of radiculopathy, three patients (8%) experienced persistent 4/5 weakness, and the remaining patients were normal.,

including four patients in. whom diagnosis was delayed.

The six patients with SO improved significantly. 'Persistent neck pain was seen in nine cases (18%). Although the lateral mass plates and inter-spinous cable are stronger, easier to place, and significantly lessened the amount of resultant kyphosis ($p<0.02$), the results of chi-square analysis demonstrated only a slight trend for improved clinical outcome compared with the use of wire and iliac crest (P=O, 1)

NOTES:

Image-Guided Surgery of the Spine: An Update

Gerald Rodts, M.D., Kevin Foley, M.D.

The use of intraoperative image-guidance in spinal surgery has historically relied upon plain radiographs or live fluoroscopy. With the increasing use of internal fixation, there is a greater need for technology that assists in the accurate placement of spinal implants. The limitations of radiography and fluoroscopy are significant. Recently, stereotactic technology has been applied successfully for use in spinal surgery. There are specific clinical situations in which this new technology offers unequaled ability to navigate through difficult 3-dimensional anatomy. As a result, stronger, more biomechanically-sound contructs can be assembled.

One of the drawbacks of intraoperative frameless spinal stereotaxy is the need to obtain a pre-operative data set. Another drawback is the current inability to update that data set in the operating room after changing a patientís alignment, reducing a fracture fragment, distracting or compressing the spine, etc. Additionally, frameless stereotaxis requires intraoperative registration of the anatomy. A new technology based on conventional fluoroscopy and incorporating stereotactic strategies allows for simple acquisition of a data set with a single x-ray, automatic registration/calibration, and virtual navigation of common spinal instruments based on the acquired fluoroscopic image. Virtual fluoroscopy eliminates repeated (excessive) radiation exposure to a surgeon over time, eliminates many of the time-consuming steps involved in frameless spinal stereotaxis, but allows the surgeon to navigate virtual representations of real instruments in-hand through an acquired fluoroscpic image (e.g. lateral lumbar view). In addition to defining these two forms of image-guidance technology, we will review our clinical experience with spinal stereotaxis and virtual fluoroscopy.

Developing New Technology: An Accurate Laser Targeting System for Fluoroscopically Assisted Procedures

Michael K. Landi, MD

University at Buffalo Neurosurgery

Objective: A laser targeting system was developed for fluoroscopically assisted procedures. It positions a laser beam collinear with a line of x-ray radiation from the source to the detector. The system allows the operator to image and target a deep tissue structure, turn off the x-ray irradiation and use the laser as a guide to the target.

Methods: The device mounts on the x-ray source of a mobile c-arm fluoroscope. X-rays pass through a radiolucent calibration chamber containing radio-opaque cross hairs. A laser beam is reflected, from a radiolucent mirror, along the axis of the chamber through the centers of the cross hairs. The x-ray image is undistorted and displays the two cross hairs. A remote control drives the chamber into calibration such that the images of the two cross hairs are superimposed, providing a radiographic image of the laser axis.

Results: The FDA accepted device has been used for percutaneous vertebroplasty, vertebral body biopsy, trigeminal radiofrequency rhizotomy, bone tumor biopsy, far lateral disc localization, pedicle screw placement, facet blocks and rhizotomy, brain tumor biopsy/localization, distal locking screw placement, and lung biopsy. The device demonstrated accurate localization.

Conclusion: The laser targeting system provides a simple method for localizing a deep internal structure using fluoroscopy. It provides an accurate surface point of entry and angle of approach to deep internal structures eliminating the need for x-ray irradiation during target approach. The process of developing technology conceived by clinicians from concept to commercial product is reviewed.

Outcomes Studies in Carotid Endarterectomy

Robert E. Harbaugh M.D., F.A.C.S.
Professor of Surgery (Neurosurgery)
Dartmouth-Hitchcock Medical Center

ABSTRACT

The efficacy of carotid endarterectomy for stroke prevention in patients with high grade symptomatic and asympotomatic carotid stenosis has been extensively studied. Large, Multicenter, prospective, randomized studies have documented the benefit of this operation for reducing the risk of stoke if thc surgery cm be done with acceptably low perioperative morbidity and mortality, Because these studies documented a substantial benefit from surgery, the number of patients undergoing carotid endarterectomy in the United States has increased substantially during thc lad five years.

However, numerous studies analyzing the database maintained by the United States Health Care Financing authority (HCFA) indicate that the morbidity and mortality associated with carotid endarterectomy is considerable highter in general practice than was thc casc in thc prospective randomized studios. This raises the question as to whether or not &0 results of the prospective, randomized studies can be generally applied to patients undergoing carotid endarterectorny for stroke prevention in thc United States.

This presentation will discuss the limitations of both prospective randomized studies and large database outcomes studies, The use of a disease-specific searchable, computerized database for patients undergoing carotid endarterectomy will bc rcviewcd and thc efforts of thc Outcomes Committee of the American Association of Neurological Surgeons and Congress of Neurological Surgeons to prospectively evaluate thc outcomes of patients undergoing carotid endarterectomy using an. on-line outcomes reporting system, will be discussed.

Improved Management of Childhood Medulloblastoma Using Proton Beam Radiotherapy

Paul H. Chapman, MD; Nancy J. Tarbell, MD; William E. Butler, MD; and Jay S. Loeffler, MD

Division of Neurosurgery and Department of Radiation Oncology Massachusetts General Hospital; Boston, MA.

Radiation therapy is an integral part of the management of medulloblastoma. This typically consists of craniospinal axis irradiation for potential CSFdissemination, and post-operative x-ray boost therapy to the posterior fossa. In children, such treatment may result in failure of normal somatic growth, serious neurocognitive deficits, and disordered hypothalamic-pituitary function. Delivering enough photon radiation for adequate tumor control can be problematic in these patients. By virtue of its superior dose distribution, the proton beam offers a fundamentally new way of optimizing therapy for childhood medulloblastoma, while minimizing the risk of injury to normal tissues. Posterior fossa boost therapy excludes the temporal lobes, hypothalamus-pituitary axis, and the inner ears. The whole brain skin dose is substantially reduced; and the spinal axis can be treated without irradiating thoracic and abdominal viscera, including the ovaries in females. This approach holds great promise, not only for the treatment of medulloblastoma, but for otherdisseminating CNS malignancies in children as well.

Radical Resection of Gliomas in Functioning Brain Regions Utilizing Awake Cortical and Subcortical Mapping and Frameless Stereotaxis

Fredric B. Meyer, M.D., Lisa M. Bates, B.S., Stephan J. Goerss, B.S., Wanda L. Windschitl, R.N., Jonathan A. Friedman, M.D.

Analyzed here are the surgical techniques utilizing frameless stereotaxis combined with awake cortical and subcortical mapping to facilitate radical resection of gliomas located in functioning brain regions. Forty consecutive patients underwent awake stereotactic resection of gliomas located in eloquent cortical and subcortical regions. The goal of surgery was to resect the maximum neurologically permissible tumor volume as defined by the T2 margins on preoperative stereotactic imaging. Cytoreduction was determined by measuring preoperative and postoperative residual tumor volumes as defined by both T2 and T1 with gadolinium utilizing novel imaging software. All patients underwent postoperative detailed neurological examinations. In Grade 2 gliomas, a greater than 90% resection of the T2 signal was achieved in 8/10 patients. In Grade 3 gliomas, a greater than 90% reduction of T2 was achieved in 6/21. In Grade 4 patients, a 90% reduction in T1 gad was achieved in 7/8 but only 2/8 had greater than a 90% reduction of T2 because of location and large T2 volumes. Many lesions which on preoperative imaging were thought to be low grade gliomas proved to contain islands of higher grade neoplasm suggesting dedifferentiation. There were no perioperative deaths. One patient suffered an intraoperative seizure without sequelae. Fifteen patients suffered a neurological deterioration secondary to the radical surgery out of which 8 have recovered completely and 3 have made a significant partial recovery. Aggressive glioma resections may be associated with an improved prognosis. Often these neoplasms are infiltrative through eloquent brain regions. Combining computer guided stereotaxis with awake cortical and subcortical monitoring facilitates a radical resection with an acceptable postoperative neurological morbidity.

FasL Expression in Tumor Vesels of Patients with Glioblastoma Multiforme

John S. Yu, Yun-hui Liu, Chun-ren Liu, Ken Samoto, Moneeb Ehtasham, Keith L. Black

Tumors have evolved multiple mechanisms for evading the immune system. These range from passive failure to express costimulatory and major histocompatibility complex molecules to active processes such as expressing immunosuppressive cytokines such as TGF-beta. We are measuring potential inhibition of T-cell migration in glioma by assessing the expression of FasL in glioma and specifically in the endothelial cells of intracranial tumors. Preliminary data suggests colocalization of FasL on endothelial cells in GBM patients and less so in meningioma patients. By performing immunohistochemistry using FasL and Factor VIII we have compared these data with already established data of FACS of tumor infiltrating lymphocytes in gliomas and meningiomas. There is an inverse correlation in the number of CD8+ and CD4+ lymphocytes in tumor with FasL expression on tumor endothelial cells.

Coculturing of endothelial cells with primary GBM cells was shown to upregulate FasL on endothelial cells by Western and FACS analysis. TNF-alpha is known to downregulate FasL expression on endothelial cells. We have delivered adenovirus containing the TNF-alpha gene and demonstrated FasL downregulation on human endothelial cells. Our goal is to develop gene transfer strategies to counteract the T-cell inhibition of FasL expression on endothelial cells in patients with GBM.THURSDAY,

Stereotactic Radiosurgery: The Treatment of Choice for Jugular Foramen Region Tumors?

Bruce E. Pollock, M.D., Deborah A. Gorman, R.N.

Although many tumors affecting the jugular foramen region are histologically benign, complete tumor resection frequently results in lower cranial nerve dysfunction. As an alternative to surgical resection, thirty-two patients with tumors involving the jugular foramen underwent radiosurgery at our center between 1990 and 1998.

Pathology included glomus tumor (n=19), schwannoma (n=7), and meningioma (n=6). The mean patient age was 56 years (range, 28-83). Fourteen patients (44%) had undergone one or more prior tumor resection. Of the 14 patients having prior surgery, thirteen (93%) had lower cranial nerve deficits, three (21%) had facial palsy, and five were deaf (36%). Four of 18 patients (22%) having radiosurgery as primary management had lower cranial nerve deficits preoperatively. Multiple isocenter dose planning was used in all patients, and the mean marginal and maximum radiation doses were 18 Gy and 36 Gy, respectively. At a mean follow-up interval of 37 months (range, 12-100 months), 22 tumors were unchanged in size and 10 tumors were smaller. No patient has required any additional treatment of their tumor. Morbidity was limited to one patient having a decline in hearing (Gardner-Robinson Class II); no patient developed new or worsened lower cranial nerve function postoperatively.

Radiosurgery provides tumor growth control with low morbidity for the majority of patients with benign tumors of the jugular foramen. For patients with symptoms related to local cranial nerve involvement and not brainstem mass effect, radiosurgery may be preferred over surgical resection to minimize the risk of postoperative lower cranial nerve dysfunction.

NOTES:

NOTES:

SATURDAY, NOVEMBER 13 8:50-9:08 AM

Results of a Phase I Study of the Treatment of Malignant Gliomas with the Genetically-Engineered Herpes Simplex Virus G207

James M. Markert (1), Michael D. Medlock (3), Samuel Rabkin (3), Yancey Gillespie (1,2) Frank Feigenbaum (3), William D. Hunter (3), Tomoki Todo (3), Carlo Tornatore (4) Robert L. Martuza (3)

Affiliations:

University of Alabama at Birmingham Department of Surgery, Division of Neurosurgery (1) and Department of Microbiology (2) Georgetown University Medical Center Departments of Neurosurgery (3) and Neurology (4)

Abstract

G207 is an conditionally replication-competent derivative of Herpes Simplex Virus type-1 engineered to contain deletions of both (134.5 neurovirulence loci and a disabling lacZ sequence insertion into the UL39 gene (ribonucleotide reductase, large subunit). We have previously demonstrated that G207 efficaciously treats malignant glial tumors in mice. We sought to establish the safety of G207 inoculation into high grade glial tumors in humans. Criteria for inclusion into this multicenter dose-escalation study were the presence of a histologically proven malignant glioma, Karnofsky score >70, recurrence despite surgical and radiation therapy, and an enhancing lesion greater than one centimeter in size. Patients with isolated brainstem involvement, a history of other CNS disease, or increasing steroid dependence were excluded from the trial. Pre- and post-treatment cerebral magnetic resonance imaging studies were obtained for volumetric analysis. Each patient received a stereotactic intratumoral inoculation of G207 followed by four days of close neurologic monitoring in an in-patient setting. In February, 1998, the first patient in the study underwent inoculation with 1x106 plaque forming units (pfu) of G207. In May, 1999, the trial was closed to further enrollment after twenty-one patients had been inoculated with doses up to 3 x 109 pfu. No serious adverse events clearly related to G207 inoculation have been observed to date. Data accrual is continuing on surviving patients. Phase II studies are planned for treatment of newly-diagnosed patients. Future trials will likely employ novel HSV-1-vectors expressing foreign genes to increase the efficacy of treatment. These vectors will also be discussed.

Clinical and Economic Consequences of Early Discharge after Stereotactic Brain Biopsy

Gene H. Barnett, Wayel Kaakaji, Diane Bernhard, Kren Valaitis, Sarah Stamp, Narongsak Boonswag

Objective: To determine the clinical and economic consequences of early discharge after stereotactic brain biopsy (SBB).

Methods: The records of patients undergoing SBB in 1994 and 1995 (Group A) were reviewed for the nature and timing of perioperative (<48 hours) clinical and radiological complications. Guidelines for early discharge after SBB (below) were applied for patients from January 1996 through July 1998 (Group B). Hospital financial records for patients undergoing SBB in 1997 and 1998 were reviewed for net revenue by discharge status.

Results: Group A: 130 biopsies were performed. There were five serious complications (3.8 per cent), of which one was sustained, and one death (0.7 per cent). All complications occurred within 6 hours of surgery. Guidelines for early discharge (<8 hours) were absence of: excessive intraoperative bleeding, new postoperative deficit and clot on a delayed postoperative CT scan.

Group B: 139 biopsies were performed. There were three serious complications (2.2 per cent) of which one was sustained. All occurred within six hours of surgery.

Financial analysis: Hospital financial records were available on 96 patients of which 22 were early discharges (<8 hours), 11 were extended outpatient observations (8 - <24 hours), and the remainder inpatient (> 24 hours). Net hospital income were $946, $261 and $382, respectively across the two years, but declined to $671, -$1,339, and -$889 for 1998.

Conclusions: Extended outpatient observation is not clinically necessary in the absence of excessive intraoperative bleeding, new postoperative deficit and clot on delayed postoperative CT, and may be economically prohibitive in a teaching hospital setting.

An Ideal Syngeneic Mouse Glioma Model for Testing Immunotherapy Strategies

Warnick RE, Weiner NE, Pyles RB, Chalk CL, Balks GO Miller MA, Dyer CA, Parysek LM

Animal brain tumor models serve a vital role in the development and testing of new anticancer therapies. Since the immune system is likely to play an essential role in tumor eradication, there is a particular need for modeling brain tumors in immunocompetent hosts. Few glioma models have been developed in immunocompetent mice and none of these tumors have the histological and antigenic characteristics of glioblastoma. We have used a cell line, 4C8, derived from a spontaneous glioma that arose in a transgenic mouse, to develop a new syngeneic glioma model. The intracranial injection of 4C8 cells into immunocompetent syngeneic B6D2F1 mice resulted in tumors that were densely cellular, developed a pseudopallisading pattern of necrosis, and expressed GFAP; all important features of human glioblastoma. The average neurological endpoint was 51 days after intracranial injection. The 4C8 cells also grew rapidly in the flank reaching an average volume of 100 mm3 by 34 days postinjection. The 4C* cell line was found to be highly motile and invasive in standard Matrigel and wound filling assays. Further studies of the 4C8 cell line using green fluorescent protein are underway to better characterize its invasiveness in vivo. Overall, our results suggest that the 4C8 mouse glioma has the histological, antigenic, and growth characteristics of human glioblastoma and represents an ideal system it). which to test new therapies, especially those that rely on an immune response (e.g., gene therapy, immunotherapy),

Intraoperative Human Sensorimotor and Language Mapping Using Optical Intrinsic signal Imaging: Comparison with Electrophysiologic Techniques and fMRI in 40 Patients

Neil Martin, MD, Andrew Cannestra, PhD, Nader Pouratian, BS, Donald Becker, MD, Susan Bookheimer, PhD, Nancy Sicotte, MD, Arthur Toga, PhD

Division of Neurosurgery, Laboratory of Neuroimaging, and Ahmanson-Lovelace Brain Mapping Center, UCLA

By measuring changes in light reflectance off the cortex, optical intrinsic signal (OIS) imaging detects and maps optically-active processes coupled to neuronal activity (Haglund et al, 1992; Toga et al, 1995). This study reports the method for OIS imaging of cortical activity, and describes correlation with established techniques for functional mapping.

Methods: Intraoperative finger and face sensory stimulations were administered using a 110 Hz vibrator in awake or anesthetized patients; language stimulations (naming, reading, and speaking) were performed in awake patients. During stimulation trials, baseline and activated OIS images were obtained using a slow-scan CCD camera mounted on the operating microscope. Functional maps were generated by pixel-by-pixel subtraction of control images from stimulation images. OIS images were compared with preoperatively acquired fMRI maps or with intraoperatively acquired maps obtained using SSEP recording or direct cortical electrical stimulation. After IRB approval, forty patients with cortical tumors or AVMs were studied.

Results: OIS mapping was successful even in tumor patients with mild neurological deficits or with high-flow AVMS. OIS maps provided topographical specificity for somatosensory and language functions, and the localization of peak optical responses in individuals correlated well with electrophysiologic mapping. The agreement between OIS maps and fMRI was generally good, but while OIS mapped activation to gyral surfaces, fMRI localized signal changes more over venous structures in adjacent sulci.

Conclusion: This study suggests that OIS offers a novel, valid technique for mapping somatosensory and language function over a wide area of exposed cortex, without the need for cortical contact or repetitive electrical stimulation.

New Neurosurgical Perspectives on Spontaneous Intracrebral Hemorrhage

Issam A. Awad, MD

The Neurovascular Surgery Program, Department of Neurosurgery
Yale University School of Medicine, New Haven, Connecticut

There are many facets to spontaneous intracerebral hemorrhage (SICH) with neurosurgical considerations reflecting underlying etiology, patient age, clinical condition and hematoma size and location. We discuss novel neurosurgical perspectives from three ongoing research projects.

In elderly patients with SICH we describe an ongoing protocol of minimally invasive bedside hematoma thrombolysis and aspiration procedure. The stereotactic thrombolysis and aspiration of cerebral hematoma (STACH) protocol is currently being prepared for Phase I-II multi-institutional study of safety and feasibility, including thrombolytic dose escalation. We describe preliminary safety data from our institution in 12 cases, and the design of the proposed collaborative trial.

In younger patients with SICH there is concern about underlying etiology of hemorrhage. We present data from the Yale based Hemorrhagic Stroke Project including a population based cohort of 39 cases with SICH who survived and received complete diagnostic evaluation for underlying etiology. In 18 of these 39 cases (46%) underlying etiology remained occult to complete diagnostic evaluation. We hypothesize that hematoma evacuation with microsurgical exploration is safe and might reveal underlying etiology of SICH which might cause recurrent stroke.

We present clinical experience with 16 consecutive neurologically stable patients with SICH who underwent hematoma evacuation and microsurgical exploration after initial diagnostic evaluation failed to reveal an underlying etiology. In ten of the 16 cases (62.5%) an underlying pathology not suspected by pre-operative imaging was discovered (9 occult vascular malformation, 1 occult neoplasm). There were no surgical complications and all patients recovered fully.

We conclude that novel indications for neurosurgical intervention merit further study in individual subgroups of patients with SICH. We propose further study of minimally invasive evacuation of SICH in elderly patients, and open microsurgical exploration for etiology in younger patients even when neurologically stable.

3-D Computer Modeling of the Cerebral Vasculature

Paul S. Larson, M.D., Chuck Sites, B.S., Ashraf Mohamed, M.S., Ayman M. Eldeib, Ph.D., Todd Vitaz, M.D., Aly A. Farag, Ph.D., Thomas M. Moriarty, M.D., Ph.D. and Christopher B. Shields, M.D.

Department of Neurological Surgery, School of Medicine and Computer Vision and Image Processing (CVIP) Laboratory, Department of Engineering, University of Louisville, Louisville, KY

INTRODUCTION: We describe a method to create fully interactive 3-D computer models of cerebral arterial anatomy using preoperative MRI data. METHODS: Software was developed using Silicon Graphics UNIX workstations. Volunteers were recruited to undergo MRI for building the computer models and magnetic resonance arteriography (MRA) for comparative analysis. RESULTS: A single T1-weighted axial MRI slice is viewed by the surgeon, and a computer program previously developed in our lab is used to identify arterial ìflow voidsî. A mathematical paradigm is then employed to identify areas in the adjacent MR slices that are connected to the flow voids in the original MR image. The process is automatically repeated throughout the image volume, and the final 3-D model is displayed. The entire process can be accomplished in under 30 seconds. The operator can use a mouse to navigate around the model from any distance or perspective. 3-D models were created from MRI scans of volunteers and compared with MRA of the same individuals. The 3-D models were found to be anatomically accurate and had a high degree of correlation with the subjectís MRA. CONCLUSION: This experimental technique is rapid, accurate and provides the surgeon with unique information regarding the geometry of aneurysms and other vascular malformations. It has potential application in the planning and execution of traditional craniotomy, intraoperative MR-guided craniotomy and radiosurgery for a variety of vascular lesions.

Instrumented Fusion in the Management of Post Laminectomy Lumbar Spinal Stenosis

Charles L. Branch, David Jones

Objective: While the indications for and the effectiveness of decompressive laminectomy have been well documented, there is uncertainty regarding the use of fusion and instrumentation in degenerative spinal disorders. This retrospective review was designed to assess the outcome of repeat decompression and instrumented fusion for post-laminectomy lumbar spinal stenosis.

Methods/Results: Over a ten-year period, 43 patients with chronic low back and/or leg pain underwent repeat decompressive lamiectomy an instrumented fusion for recurrent and/or residual lumbar spinal stenoiss. These patients had undergone a total of 51 previous decompressive laminectomies without fusion for lumbar stenosis. The mean interval between the preceding decompressive procedure and subsequent fusion was 2.67 years. The average age of the patients was 66.4 years, and the average number of levels fused was 2.8. Outcome in terms of pain relief and functional imporvement was determined by chart review. With a mean follow-up of 1.46 years, an overall improvement was achieved in 77% of patients. Additionall, 35 patients responded to a questionnaire (mean follow-up 3.26 years) in which they graded their outcomes as much imporved (51.4%) somewhat improved (37.1%), unchanged (11.4%), somewhat worse (0%), and much worse (0%). Five (11.6%) patients required an additional 7 lumbar spine operations for adjacent level stenosis at a mean interval of 1. 93 years after fusion.

Conclusions: Long-term improvement was attained in approximately 80% of patients who underwent repeat lumbar decompression and instrumented fusion for post-laminectomy spinal stenosis. However, fusion may accelerate degeneration at adjacent levels necessitating additional lumbar spine operations.

Early Moderate Hyperventilation does not Reduce Cerebral Metabolism Following Severe Traumatic Brain Injury.

Robert L. Grubb, Thomas Videen, Allyson R. Zazulia, Ellen Deibert, Venkadesh Aiyagari, Ralph G. Dacey, Michael N. Diringer, William J. Powers

Hyperventilation (HV) has been used for many years in managing patients with traumatic brain injury (TBI). Several studies have reported reduced cerebral blood flow (CBF) early after severe TBI. This has led to concerns that HV could cause cerebral ischemia, especially if used early after TBI. We tested the hypothesis that moderate HV early after TBI would not produce a reduction in CBF severe enough to reduce cerebral oxygen metabolism.

Nine patients were studied with positron emission tomography (PET) 11.2 ((1.6 SD) (range 8-14) hours after TBI. Glasgow Coma Scale (GCS) was 5.6 ((1.8 SD), and age was 27 ((9 SD) years. Eight patients were males. Intracranial pressure (ICP), mean arterial blood pressure (MABP) and jugular venous oxygen content were monitored. Cerebral perfusion pressure (CPP) was maintained at >70 mm Hg, using vasopressors when needed. Measurements of CBF, cerebral blood volume (CBV), cerebral oxygen utilization (CMRO2), oxygen extraction fraction (OEF) and cerebrovenous oxygen content (CvO2) were made before and after thirty minutes of HV to a PaCO2 of 30 ((2 SD) mm Hg. Ten healthy age-matched volunteers were used as normocapnic controls.

There were no differences in global CBF, CBV, and CvO2 between the TBI and control groups. In the TBI patients global CMRO2 and OEF were reduced (1.59 (0.44 SD ml/100g/min, $p<0.01$ and 0.31 (0.06 SD, $p<0.0001$ respectively). During HV global CBF fell 25.5 ((8.7 SD) ml/100g/min ($p<0.0009$), CBV fell to 2.8 ((0.56 SD) ml/100g ($p<0.001$), OEF rose to 0.45 ((0.13 SD) ($p<0.02$), and CvO2 fell to 8.3 ((3.0 SD) vol% ($p<0.02$). CMRO2 did not change.

Early, brief, moderate HV does not appear to impair cerebral metabolism in patients with severe TBI and thus is not likely to cause further neurologic injury. Additional studies are necessary to assess the effect of more severe HV and the effect of HV in patients with increased ICP.

Intracranial Hypertension and Cerebral Perfusion Pressure: Their Influences on Neurological Deterioration and Outcome in Severe Head Injury

N. Juul, GF Morris, SB Marshall, The Executive Committee of the International Selfotel Trial, L F Marshall

Background: Recently management of severe head injury has placed a renewed emphasis on elevating cerebral perfusion pressure (CPP) defined as the mean arterial pressure (MAP) minus intracranial pressure (ICP). Some have suggested that CPP is more important in influencing outcome than intracranial hypertension.

Methods: We examined the relative contribution to outcome of these two parameters in a trail of 427 patients prospectively studied in an international multi-center randomized double blind trail of the NMDA antagonist drug Selfotel.

Results: Excluding 18 patients lost to follow up, mortality rose from 9.6% in patients who had no objectively defined episodes of neurologic deterioration (n-292) to 56.5% in patients who suffered one or more episodes of neurologic deterioration (n=117). Correspondingly, favorable outcome,, defined as good or moderate on the Glasgow Outcome Scale (GOS) at six months, fell from 67.8% to 29.1 % in the presence of neuroworsening. In patients who had objective evidence of neurological deterioration, the relative influence on outcome of ICP and CPP was assessed. The most powerful predictor of neurological worsening was the presence of intracranial hypertension (ICP > 20) 20) either initially or during neurologic deterioration. There was no correlation with the CPP as long as the CPP was > 60 mmHg.

Conclusion: Treatment protocols for the management of severe head injury should emphasize the immediate reduction of increased ICP to below 20 mmHg if possible. CPP above 60 mmHg appears to have little influence on the outcome of patients with severe head injury.

Fluorescence-guided Surgery of Malignant Gliomas Utilizing 5ALA-induced porphyrins. Experience with 66 consecutive patients.

H.-J. Reulen, R Baurnigartner, W, Stummer

Department of Neurosurgery, Laser Research Laboratory, Klinikurn Grosshadern Ludwig-Maixmilians University, Munich Germany

Background: Prognosis of patients suffering from malignant gliomas depends on the completeness of tumor resection, However, malignant glioma borders are often difficult to distinguish intra-operatively, We have demonstrated 5-aminolevulinic acid (5-ALA) to induce the accumulation of fluorescent protoporphyrin IX in malignant gnomes, a phenomenom exploitable for enhancing resection of this tumor entity. We now analyze the influence of fluorescence - guided resection on post-operative magnetic resonance imaging (MRI) and survival.

Methods: Sixty-six consecutive patients with malignant glioma operated on in our department received 20 mg 5-ALA/kg b.w. orally 3 hours prior to anesthesia. Intra-operatively, tumor fluorescence was visualized using a modified operating microscope. Visible fluorescence was removed whenever considered safely possible. Post-operative .MRI was obtained within 72 hours for assessment of residual contrast enhancement. Patient survival was analyzed using the Kaplan-Meier method and multivariate analysis considering Karnofsky status, age, histology and degree of resection, as determined from early post-operative MRI. The present series was compared to 89 consecutive patients operated on between 1990 and 1992.

Results: Complete resection of enhancing tumor was accomplished in 62 % of patients. In 35 %, residual enhancement on MRI was predicted by residual intra-operative tissue fluorescence intentionally left un-resected. Karnofsky status, residual fluorescence and abscesses of contrast-enhancement on MCI were independent explanatory factors for survival, Compared to the historical series, overall survival using 5-ALA was significantly prolonged. No peri-operative mortality and only one case of permanent morbidity were encountered.

Conclusions: our observations demonstrate that resection guided by 5-ALA-induced tumor fluorescence enhances resection safely, and prolongs survival in-patients suffering from malignant California.

Genetically Engineered Cytotoxic T Lymphocytes Targeted Against Angiogenesis: A Novel Anti-Glioma Strategy

Zoher Ghogawala, MD, Bob Carter, MD, Tom Niederman, MD, PhD, and Richard C. Mulligan, PhD

This study joins two previously unrelated areas of research in order to redirect the cytotoxic T cell against an important marker of angiogenesis. This work raises the novel concept that a cytotoxic T cell genetically engineered to express a recombinant T cell receptor (TCR) bearing vascular endothelial growth factor (VEGF) as its extracellular ligand might recognize angiogenic endothelial cells by binding a receptor called Flk-1, which is expressed almost exclusively on dividing endothelial cells.

A VEGF-chimeric TCR was created and cloned into the CMMP retroviral vector. Mouse T cells were transduced with retroviral particles produced after transient transfection of 293 GPG (VSV G) viral producing cells. T cells expressing the VEGF-TCR were able to kill Flk-1 expressing cells without any toxic effect upon control cells in cytotoxicity studies. Adoptive transfer of genetically transduced murine T cells in mouse tumor models demonstrated a significant anti-tumor effect in three tumor models: GL 261 (murine glioma), Lewis lung carcinoma, and B16 melanoma. The effect of the VEGF-T cells in these models appeared to wane with time, but the ability to prolong survival and to inhibit tumor growth was very encouraging in all three models.

We have created the first functional chimeric TCR directed against an endothelial receptor (Flk-1), which is specifically upregulated in angiogenesis. The ability to target cells mediating angiogenesis raises the intriguing possibility that T cells directed against angiogenesis might function to inhibit tumor growth and prolong survival in angiogenic tumors including glioblastoma.

Elevation of the Internal Auditory Canal Pressure by Vestibular Schwannomas

Behnam Badie, MD, Mark Pyle, MD, Peter Nguyen, MD

Department of Neurological Surgery and Division of Otolaryngology (MP) University of Wisconsin School of Medicine, Madison, Wisconsin 53792.

The exact mechanism of hearing loss, the most common presenting symptom in patients with vestibular schwannomas, remains unclear. To test whether mechanical injury from tumor growth in the internal auditory canal (IAC) is responsible for this clinical finding, we measured the intracanalicular pressure (ICaP) in patients undergoing a retrosigmoid approach for tumor excision.

Before drilling of the IAC, the ICaP in 15 consecutive patients was measured using a Codman pressure sensor. The pressure readings were then correlated to the tumor size and patient's preoperative hearing status.

Placement of the pressure monitor into the IAC revealed a biphasic waveform in every patient with a mean ICaP of 20 mm Hg (range 1-45 mm Hg). The ICaP directly correlated with the proportion of tumor in the IAC ($r2=0.57$, $p=0.001$) but not with the total tumor size ($r2=0.16$, $p=0.13$). Furthermore, 8 patients with class A preoperative hearing (American Academy of Otolaryngology-Head and Neck Surgery classification) tended to have lower ICaP's as compared to 5 patients with class B hearing (16+5 Vs 28+ 4). Although this observation suggested an inverse correlation between the ICaP and hearing function, the difference between the two groups was not statistically significant ($p=0.14$).

Pressure on the cochlear nerve as a result of intracanalicular tumor growth may be responsible for hearing loss in-patients with vestibular schwannomas. Modification of surgical techniques to address the elevated ICaP during tumor resection, such as early drilling of the IAC, may be beneficial in improving postoperative hearing function in these patients.

NOTES:

NOTES:

Special Guests

GUESTS	SPONSORS
David Andrews, M.D. Philadelphia, PA	Robert Rosenwasser, M.D.
Armand Awad, M.D. New Haven, CT	Issam Awad, M.D.
Behnam Badie, M.D. Madison, WI	Robert Dempsey, M.D.
Gene Barnett, M.D. Cleveland, OH	Joseph F. Hahn, M.D.
Joshua Dowling, M.D. St. Louis, MO	Ralph Dacey, Jr., M.D.
Kevin Kaufman, M.D. Indianapolis, IN	Paul Nelson, M.D.
Carl Lauryssen, M.D. St. Louis, MO	Ralph Dacey, Jr., M.D.
Paul Larson, M.D. Louisville, KY	Christopher Shields, MD
Robert Maciunas, M.D. Rochester, NY	Warren Selman, MD
James Markert, M.D. Birmingham, AL	Julian Hoff, M.D.
Stephen Papadopoulos, M.D. Ann Arbor, MI	William Chandler, M.D.
Bruce Pollock, M.D. Rochester, MN	Fred Meyer, M.D.
Charles C. Rich, M.D. Salt Lake City, UT	J. Charles Rich, M.D.
Daniel Robertson,M.D. Olive Branch, MS	James Robertson, M.D.
Gerald Rodts, M.D. Atlanta, GA	Suzie Tindall, M.D.
Philip Stieg, M.D. Boston, MA	Peter M. Black, M.D., Ph.D.
Bruce Sorensen, M.D. Salt Lake City, UT	J. Charles Rich, M.D.
Ronald Warnick, M.D Cincinnati, OH	Harry VanLoveren, M.D.
Christopher Wolfla, M.D. Edmond, OK	Christopher Loftus, M.D.

Academy Award Winners

Paul M. Lin 1955
Hubert L. Rosomoff 1956
Byron C. Pevehouse 1957
Norman Hill 1958
Jack Stern 1959
Robert Ojemann 1960
Lowell E. Ford 1962
Charles H. Tator 1963
Earle E. Crandall 1964
Stephen Mahaley, Jr. 1965
Chun Ching Kao 1966
John P. Kapp 1967
Yoshio Hosobuchi 1968
Gary G. Ferguson 1970
Richard L. Pressley 1971
David G. McLone 1972
Arden F. Reynolds, Jr. 1973
Richard L. Rapport 1974
Andrew G. Shetter 1975
John R. Howe 1976
Howard W. Blume 1977
Howard J. Senter 1978
Elisabeth M. Post 1979
David Dubuisson 1980
Dennis A. Turner 1981
Marc R. Bayberg 1982
David S. Baskin 1983
Kevin J. Kiwak 1984
Terry Lichtor 1985
Michael G. Nosko 1986
Joseph R. Madsen 1987
James T. Rutka 1988
Christopher D. Heffner 1989
Scott I. Gingold 1990
Mary Louise Hlavin 1991
Adam P. Brown 1992
Michael Tymianski 1993
David Garrett, Jr 1994
L. Brannon Thomas 1995
John S. Yu 1996
Gregory Canute 1997
Nathan R. Selden 1998

Meetings of the Academy

Hotel Netherland Plaza, Cincinnati, Ohio ..... October 28-19, 1938
Roosevelt Hotel, New Orleans, Louisiana ..... October 27-19, 1939
Tudor Arms Hotel, Cleveland, Ohio ..... October 21-22, 1940
Mark Hopkins Hotel, San Francisco, California ..... November 11-15,1941
Ambassador Hotel, Los Angelas, California ..... November 11-15, 1941
The Palmer House, Chicago, Illinois ..... October 16-17, 1942
Hart Hotel, Battle Creek, Michigan ..... September 17-18, 1943
Ashford General Hospital,
White Sulphur Springs, West Virginia ..... September 7-9, 1944
The Homestead, Hot Springs, Virginia ..... September 9-11, 1946
Boardmoor Hotel, Colorado Springs, Colorado ..... October 9-11, 1947
Windsor Hotel, Montreal, Canada ..... September 20-22, 1948
Benson Hotel, Portland, Oregon ..... October 25-27, 1949
Mayo Clinic, Rochester, Minnesota ..... September 28-30, 1950
Shamrock Hotel, Houston, TX ..... October 4-6, 1951
Waldorf-Astoria Hotel, New York City ..... September 29-October 1, 1952
Biltmore Hotel, Santa Barbara, California ..... October 12-14, 1953
Broadmoor Hotel, Colorado Springs, Colorado ..... October 21-23, 1954
The Homestead, Hot Springs, Virginia ..... October 27-29, 1955
Camelback Inn, Phoenix, Arizona ..... November 8-10, 1956
The Cloister, Sea Island, Georgia ..... November 11-13, 1957
The Royal York Hotel, Toronto, Canada ..... November 6-8, 1958
Del Monte Lodge, Pebble Beach, California ..... October 18-21, 1959
Copley Sheraton Plaza, Boston, Massachusetts ..... October 5-8, 1960
Royal Orleans, New Orleans, Louisiana ..... November 7-10, 1962
El Mirador, Palm Springs, California ..... October 23-26, 1963
The Key Biscayne, Miami, Florida ..... November 11-14, 1964
Terrace Hilton Hotel, Cincinnati, Ohio ..... October 14-16, 1965
Fairmont Hotel & Towers, San Francisco, California ..... October 17-19, 1966
The Key Biscayne, Miami, Florida ..... November 8-11, 1967
Broadmoor Hotel, Colorado Springs, Colorado ..... October 6-8, 1968
St. Regis Hotel, New York City ..... September 21, 1969
Camino Real, Mexico City ..... November 18-21, 1970
Sahara-Tahoe Hotel, Stateline, Nevada ..... September 26-30, 1971
New College, Oxford, England ..... September 4-7, 1972
Huntington-Sheraton Hotel, Pasadena, California ..... November 14-17, 1973
Southampton Princess Hotel, Bermuda ..... November 6-9, 1974

The Wigwam (Litchfield Park),Phoenix, Arizona ..... November 5-8, 1975
Mills Hyatt House, Charleston,South Carolina ..... November 10-13, 1976
Mauna Kea Beach Hotel, Kamuela, Hawaii ..... November 2-5, 1977
Hotel Bayerischer Hof, Munich, Germany ..... October 22-25, 1978
Hyatt Regency, Memphis, Tennessee ..... November 7-10, 1979
Waldorf Astoria, New York City ..... October 1-4, 1980
Sheraton Plaza, Palm Springs, California ..... November 1-4, 1981
Ritz-Carlton Hotel, Boston, Massachusetts ..... October 10-13, 1982
The Lodge at Pebble Beach, California ..... October 23-26, 1983
The Homestead, Hot Springs, Virginia ..... October 17-20, 1984
The Lincoln Hotel Post Oak, Houston, Texas ..... October 27-30, 1985
The Cloister, Sea Island, Georgia ..... November 5-8, 1986
Hyatt Regency, San Antonio, Texas ..... October 7-10, 1987
Omni Netherland Plaza, Cincinnati, Ohio ..... September 13-17, 1988
Loews Ventana Canyon,Tucson,
Arizona ..... September 27-October 1, 1989
Amelia Island Plantation, Amelia Island, Florida ..... October 2-7, 1990
Salishan Lodge, Gleneden Beach, Oregon ..... September 22-26, 1991
Ritz-Carlton Hotel, Naples, Florida ..... October 21-25, 1992
The Wigwam, Phoenix, Arizona ..... October 27-30, 1993
The Cloister, Sea Island, Georgia ..... November 3-6, 1994
Loewis Ventana Canyon Resort, Tucson, Arizona ..... November 1-5, 1995
The Greenbrier, White Sulphur Springs,
West Virginia ..... September 18-22, 1996
Rimrock Resort, Banff, Alberta, Canada ..... September 10-14, 1997
Four Seasons Biltmore, Santa Barbara, California ..... November 4-7, 1998
Ritz Carlton, Amelia Island, Florida ..... November 10-13, 1999

FUTURE MEETINGS:
The Broadmoor, Colorado Springs, Colorado ..... October 11-14, 2000
Colonial Williamsburg Williamsburg,
Virginia ..... October 28-November 3, 2001

Past Presidents

Dean H. Echols 1938-39
Spence Braden 1940
Joseph P. Evans 1941
Francis Murphey 1942
Frank H. Mayfield 1943
A. Earl Walker 1944
Barnes Woodhall 1946
William S. Keith 1947
Howard A. Brown 1948
John Raaf 1949
E. Harry Botterell 1950
Wallace B. Hamby 1951
Henry G. Schwartz 1952
J. Lawrence Pool 1953
Rupert B. Raney 1954
David L. Reeves 1955
Stuart N. Rowe 1956
Arthur R. Elvidge 1957
Jess D. Herrmann 1958
Edwin B. Boldrey 1959
George s. Baker 1960
C. Hunter Shelden 1961-62
Samuel R. Snodgrass 1963
Theodore B. Rasmussen 1964
Edmund J. Morrissey 1965
George Maltby 1966
Guy L. Odom 1967
James G. Galbraith 1968
Robert H. Pudenz 1969-70
William B. Scoville 1971
Robert L. McLaurin 1972
Lyle A. French 1973
Benjamin B. Whitcomb 1974
John R. Green 1975
William H. Feindel 1976
William H. Sweet 1977
Arthur A. Ward 1978
Robert B. King 1979
Eben Alexander, Jr. 1980
Joseph Ransohoff II 1981
Byron C. Pevehouse 1982
Sidney Goldring 1983
Russell H. Patterson, Jr. 1984
Thomas Langfitt 1985
Phanor L. Perot, Jr. 1986
Shelley N. Chou 1987
James T. Robertson 1988
Thoralf Sundt, Jr. 1989
Robert Ojemann 1990
Nicholas Zervas 1991
Henry Garretson 1992
George Tindall 1993
William A. Buchheit 1994
David L. Kelly, Jr. 1995
John M. Tew, Jr. 1996
Julian T. Hoff 1997
Edward Connolly 1998

Past Vice-Presidents

Francis Murphey 1941
William S. Keith 1942
John Raaf 1943
Rupert B. Raney 1944
Arthur R. Elvidge 1946
John Raaf 1947
Arthur R. Elvidge 1948
F. Keith Bradford 1949
David L. Reeves 1950
Henry G. Schwartz 1951
J. Lawrence Pool 1952
Rupert B. Raney 1953
David L. Reeves 1954
Stuart N. Rowe 1955
Jess D. Herrmann 1956
George S. Baker 1957
Samuel R. Snodgrass 1958
C. Hunter Shelden 1959
Edmund Morrissey 1960
Donald F. Coburn 1961-62
Deben Alexander, Jr. 1963
George L. Maltby 1964
Robert Pudenz 1965
Francis A. Echlin 1966
Benjamin Whitcomb 1967
Homer S. Swanson 1968
Augustus McCravey 1969-70
Edward W. Davis 1971
John R. Green 1972
George J. Jayes 1973
Richard L. DeSaussure 1974
Ernest W. Mack 1975
Frank E. Nulsen 1976
Robert S. Knighton 1977
Robert G. Fisher 1978
H.T. Ballantine, Jr. 1979
George Ehni 1980
Courtland H. Davis, Jr. 1981
John F. Mullan 1982
Hugo Rizzoli 1983
James W. Correll 1984
E. Bruce Hendrick 1985
Griffith R. Harsh III 1986
Ellis B. Keener 1987
Robert Grossman 1988
Jim Story 1989
John Jane 1990
Stewart Dunsker 1991
Burton Onofrio 1992
Martin Weiss 1993
John M. Tew, Jr. 1994
John Van Gilder 1995
Edward Connolly 1996
George Ojemann 1997
Charles H. Tator 1998

Past Secretary-Treasurers

Francis Murphey 1938-40
A. Earl Walker 1941-43
Theodore C. Erickson ... 1944-47
Wallace B. Hamby 1948-50
Theodore B. Rasmussen 1951-53
Eben Alexander, Jr. 1954-57
Robert L. McLaurin 1958-62
Edward W. Davis 1963-65
Robert G. Fisher 1966-68
Byron C. Pevehouse 1969-72

Past Secretaries

Byron C. Pevehouse 1973
Russell H. Patterson, Jr.. 1974-76
Phanor L. Perot, Jr. 1977-80
John T. Garner 1981-83
James T. Robertson 1984-86
Nicholas T. Zervas 1987-89
William A. Buchheit 1990-92
Julian T. Hoff 1992-95
Roberto C. Heros 1995-98

Past Treasurers

Russell H. Patterson, Jr. 1973
Phanor L. Perot, Jr. 1974-76
John T. Garner 1977-80
James T. Robertson 1981-83
Nicholas T. Zervas 1984-86
William A. Buchheit 1987-89
Julian T. Hoff 1990-92
Roberto C. Heros 1992-95
David G. Piepgras 1995-98

HONORARY MEMBERS

	Elected
GUY LAZORTHES (Annick)	1973
26 Rue D. Aurlol 31400 Toulouse FRANCE	
VALENTINE LOGUE (Anne)	1974
16 Rowan Road London, England W6 7DU UNITED KINGDOM	
BERNARD PERTUISET	1986
Hospital de la Pitie 83 Boulevard de líHopital 75651 Paris, Cedex 13 FRANCE	
KEIJI SANO (Yacko)	1975
Fuji Brain Institute 270-12 Sugita Fujinomiya, 4180021 JAPAN	

SENIOR MEMBERS

	Elected
EBEN ALEXANDER, JR. (Betty) Wake Forest School of Medicine Medical Center Boulevard Winston-Salem, NC 27157-1002	1950
JAMES AUSMAN (Carolyn) Neurosurgery, MC799 Univ. of Illinois at Chicago 912 South Wood Street Chicago, IL 60612-7329	1979
DONALD BECKER (Maria) Neurosurgery, Box 957039 UCLA Medical Center 10833 Le Conte Avenue Los Angeles, CA 90095-7039	1990
GILLES BERTRAND (Louise) Montreal Neurological Institute 3801 University Street Montreal, Quebec H3A 2B4 CANADA	1967
JERALD BRODKEY (Arielle) P.O. Box 18090 Cleveland, OH 44118-0090	1977
WILLIAM BUCHHEIT (Christa) Am Nordtor 21 Espelkamp 32339 GERMANY	1980
HARVEY CHENAULT (Billee) 6340 Briarhill Road Paris, KY 40361-9063	1949
SHELLEY CHOU (Jolene) 183 Galtier Place Shoreview, MN 55126	1974

W. KEMP CLARK (Fern) 1970
3909 Euclid Avenue
Dallas, TX 75205-3103

WILLIAM COLLINS, JR. (Gwendolyn) 1963
Neurosurgery, Box 208082
Yale University
333 Cedar Street
New Haven, CT 06520-8082

EDWARD CONNOLLY (Elise) 1972
Ochsner Clinic
1514 Jefferson Highway
New Orleans, LA 70121-2429

JAMES CORRELL (Cynthia) 1966
249 Olde Point Road
Hampstead, NC 28443

COURTLAND DAVIS, JR. (Carrie Chamberlain) 1967
2525 Warwick Road
Winston-Salem, NC 27104

RICHARD DESAUSSURE, JR. (Phyllis) 1962
4290 Heatherwood Lane
Memphis, TN 38117-2302

DONALD DOHN (Carolyn) 1968
P.O. Box 998
Moss Point
Pt. Clear, AL 36564-0998

WILLIAM FEINDEL (Faith) 1959
Montreal Neurological Institute
3801 University Street
Montreal, Quebec H3A 2B4
CANADA

ROBERT FISHER (Constance) 1955
87 Shore Drive North
Bristol, NH 03222

ELDON FOLTZ (Catherine) 1960
UCI Medical Center
Bldg. 3, Rm. 313, Route 81
101 The City Drive South
Orange, CA 92868

RICHARD FRASER (Sara Ann) 1976
525 East 68th Street
New York, NY 10021

LYLE FRENCH (Gene) 1954
P.O. Box 1007
Pauma Valley, CA 92061-1007

JOHN GARNER (Candace) 1971
67 Hillsdale Drive
Newport Beach, CA 92660-4235

HENRY GARRETSON (Marianna Schantz) 1973
Neurological Surgery, Suite 1102
University of Kentucky
210 East Gray Street
Louisville, KY 40202-3907

SIDNEY GOLDRING (Lois) 1964
Neurosurgery, CB-8057
Washington University
660 South Euclid
St. Louis, MO 63110-1094

PHILIP GORDY (Silvia) 1968
3601 Carmel Drive
Casper, WY 82604-4949

ROBERT GROSSMAN (Ellin) 1984
Department of Neurosurgery
Baylor College of Medicine
One Baylor Place
Houston, TX 77030

GRIFF HARSH, III (Craig) 1980
P.O. Box 232
Sweetwater, TN 37874-0232

MAJOR GEN. GEORGE HAYES 1962
Apartment 113
221 Booth Street
Gathersburg, MD 20878

MARK PETER HEILBRUN (Robyn) 1984
Neurosurgery, #313406
University of Utah
50 North Medical Drive
Salt Lake City, UT 84132

E. BRUCE HENDRICK (Gloria) 1968
63 Leggett Avenue
Toronto, Ontario M9P 1X3
CANADA

JULIAN T. HOFF (Diane) 1975
Neurosurgery, TC 2128
University of Michigan
1500 East Medical Center Drive
Ann Arbor, MI 48109-0338

HAROLD HOFFMAN (Jo Ann) 1982
The Hospital for Sick Children
555 University Avenue
Toronto, Ontario M5G 1X8
CANADA

EDGAR HOUSEPIAN (Marion Grace Lyon) 1976
The Neurological Institute
710 West 168th Street
New York, NY 10032-2603

ALAN HUDSON (Susan) 1978
The Toronto Hospital, Bell Wing 1-658
585 University Avenue
Toronto, Ontario M5G 2C4
CANADA

JOHN JANE, SR. (Noella) 1982
Neurosurgery, Box 212
University of Virginia
Health Science Center
Charlottesville, VA 22908

PETER JANNETTA (Diana) 1994
Neurosurgery, Suite B-400
Presbyterian University Hospital
230 Lothrop Street
Pittsburgh, PA 15213-2582

ELLIS KEENER (Ann) 1978
915 East Lake Drive, N.W.
Gainesville, GA 30508-1729

DAVID KELLY, JR. (Sarah {Sally}) 1975
Department of Neurosurgery
Wake Forest University
Medical Center Boulevard
Winston-Salem, NC 27157-1029

WILLIAM KELLY (Joan) 1977
Apartment B102
16925 Inglewood Road NE
Bothell, WA 98011

ROBERT KING (Molly Gibbs) 1958
Department of Neurosurgery
State University of New York
750 East Adams Street
Syracuse, NY 13210-2306

WOLFF KIRSCH (Marie-Claire) 1971
1360 Prospect
Redlands, CA 92373

ROBERT KNIGHTON (Louise) 1966
9288 Avenida San Timoteo
Cherry Valley, CA 92223-4314

THEODORE KURZE (Joan) 1967
Suite D
510 31st Street
Newport Beach, CA 92663-3806

THOMAS LANGFITT (Carolyn) 1971
Glenmede Corporation
One Liberty Place, Suite 1200
1650 Market Street
Philadelphia, PA 19103-7391

SANFORD LARSON (Jackie) 1989
Department of Neurosurgery
Medical College of Wisconsin
9200 West Wisconsin Avenue
Milwaukee, WI 53226

RAEBURN LLEWELLYN (Carmen Rolon) 1963
Unit 6D
3 Poydras Street
New Orleans, LA 70130-1665

DON LONG (Harriett) 1983
Neurosurgery, Meyer 7-109
Johns Hopkins Medical School
600 North Wolfe
Baltimore, MD 21287-7709

WILLIAM LOUGHEED 1962
178 Klempenfeld Drive
Barrie, Ontario L4M 1C3
CANADA

JOHN LOWREY (Catherine {Katy}) 1965
Box 6989
Kamuela, HI 96743-6989

ALFRED LUESSENHOP (Frances) 1977
Department of Neurosurgery
Georgetown University Hospital
3800 Reservoir Road
Washington, DC 20007

ERNEST MACK 1956
235 Juniper Hill Road
Reno, NV 89509-2935

LEONARD MALIS (Ruth) 1973
219-44 Peck Avenue
Hollis Hills, NY 11427-1122

ROBERT MCLAURIN (Sarah) 1955
900 4th & Vine Tower
Cincinnati, OH 45202

JOHN MULLAN (Vivian Dunn) 1963
5844 Stony Island Avenue
Chicago, IL 60637-2022

BLAINE NASHOLD, JR. (Irene) 1967
Division of Neurosurgery
Box 3807
Duke University Medical Center
Durham, NC 27710-0001

GUY ODOM 1946
2812 Chelsea Circle
Durham, NC 27707-5133

ROBERT OJEMANN (Jean) 1968
Neurosurgery Service
Massachusetts General Hospital
Fruit Street
Boston, MA 02114

BURTON ONOFRIO (Judith) 1975
1105 Tenth Street SW
Rochester, MN 55905

RUSSEL PATTERSON, JR. (Julie) 1971
Apartment #65A
146 West 57th Street
New York, NY 10019-3301

SYDNEY PEERLESS (Ann) 1977
Neurosurgery, Suite 209
Mercy Neuroscience Institute
3661 South Miami Avenue
Miami, FL 33133-4206

PHANOR PEROT, JR. 1970
Neurosurgery, 428 CSB
Medical Univ. of South Carolina
96 Jonathan Lucas Street
Charleston, SC 29425

BYRON CONE PEVEHOUSE (Lucy) 1964
13623 32nd Place, N.E.
Bellevue, WA 98005

J. LAWRENCE POOL 1940
41 Cherry Hill Road
West Cornwall, CT 06796-0041

ROBERT PORTER (Dean) 1962
6461 Bixby Hill Road
Long Beach, CA 90815

JOHN RAAF (Lorene) ..... Founder
618 N.W. Westover Terrace
Portland, OR 97210-3134

AIDEN RANEY 1946
Suite 203
125 N. Las Palmas Avenue
Los Angeles, CA 90004-1047

JOSEPH RANSOHOFF, II (Lori Cohen, DDS) 1965
Suite 730, Harbourside Medical Tower
4 Columbia Drive
Tampa, FL 33606

THEODORE RASMUSSEN 1947
29 Surrey Drive
Montreal, Quebec H3P 1B2
CANADA

ALBERT RHOTON, JR. (Joyce) 1984
Neurosurgery, L2-100
University of Florida
100 South Newell Drive
Gainesville, FL 32610

HUGO RIZZOLI (Helen) 1973
6100 Kennedy Drive
Chevy Chase, MD 20815-6510

THEODORE ROBERTS (Joan) 1976
Neurosurgery, CH-50
University of Washington
P.O. Box 5371
Seattle, WA 98105

JAMES ROBERTSON (Valeria) 1971
Sofamor Danek
1800 Pyramid Place
Memphis, TN 38132

EDWARD SELJESKOG (Peggy) 1992
Neurosurgery, Suite 110
2805 Fifth Street South
Rapid City, SD 57701-7306

C. HUNTER SHELDEN 1941
Huntington Medical Research Institute
10 Rico Street
Pasadena, CA 91105-3201

WILLIAM SHUCART (Laura) 1989
Department of Neurosurgery
New England Medical Center
750 Washington Street
Boston, MA 02111

JAMES SIMMONS (Vanita) 1975
190 South Grove Park Road
Memphis, TN 38117

KENNETH SMITH, JR. (Marjorie) 1987
Division of Neurosurgery
St. Louis University
3635 Vista Avenue at Grand Boulevard
St. Louis, MO 63110-0250

ROBERT SMITH 1989
Neurosurgery, Suite 230
5903 Ridgewood Road
Jackson, MS 39211

BENNETT STEIN (Bonita) 1970
Neurosurgery, Room 204
Columbia University
710 West 168th Street
New York, NY 10032-2603

JIM STORY (Joanne) 1972
Suite 1240
315 North San Saba
San Antonio, TX 78207-3154

ANTHONY SUSEN (Patricia) 1965
193 Old Glebe Point Road
Burgess, VA 22432-9801

WILLIAM SWEET (Elizabeth) 1950
309 Goddard Avenue
Brookline, MA 02445

RONALD TASKER (Mary) 1971
Neurosurgery, McL. 2-431
Toronto Hospital, Western Division
399 Bathurst Street
Toronto, Ontario M5T 2S8
CANADA

CHARLES TATOR (Carol) 1991
Neurosurgery, McL. 2-435
Toronto Hospital, Western Division
399 Bathurst Street
Toronto, Ontario M5T 2S8
CANADA

GEORGE TINDALL (Wendy) 1968
Department of Neurosurgery
Emory University Clinic
1327 Clifton Road NE
Atlanta, GA 30322-1013

JOHN TYTUS (Virginia) 1967
3827 East Crockett Street
Seattle, WA 98112

JOHN VAN GILDER (Kerstin) 1980
Division of Neurosurgery
University of Iowa Hospitals
200 Hawkins Drive
Iowa City, IA 52242

EXUM WALKER (Nellie) 1938
735 Peachtree Battle Avenue, NW
Atlanta, GA 30327-1250

CLARK WATTS (Patricia) 1975
5922 Northwest Place
Austin, TX 78731

LOWELL WHITE, JR. (Margie) 1971
11009 East Villa Monte Drive
Mukilteo, WA 98275

ROBERT WILKINS (Gloria) 1973
Neurosurgery, Box 3807
Duke University Medical Center
Durham, NC 27710-0001

CHARLES WILSON (Francie Petrocelli) 1966
Neurological Surgery, Room U-125
Univ. of California, San Francisco
533 Parnassus Avenue
San Francisco, CA 94143-0112

DAVID YASHON (Christine) 1972
Suite 1201
1492 East Broad Street
Columbus, OH 43205-1546

HAROLD YOUNG (M. Theresa) 1994
Neurosurgery, Box 980631
Medical College of Virginia Station
Richmond, VA 23298

NICHOLAS ZERVAS (Thalia) 1972
Neurosurgery, White 502
Massachusetts General Hospital
Fruit Street
Boston, MA 02114-2698

ACTIVE MEMBERS

Elected

MICHAEL APUZZO (Helene) 1988
Neurosurgery, Suite 5046
University of Southern California
1200 North State Street
Los Angeles, CA 90033-4525

ISSAM AWAD (Catherine) 1996
Neurosurgery, TMP 405
Yale University
333 Cedar Street
New Haven, CT 06520-3206

DANIEL BARROW (Mollie Winston) 1993
Neurosurgery, Suite 2200
The Emory Clinic
1365 Clifton Road NE
Atlanta, GA 30322

H. HUNT BATJER (Janet) 1996
Neurosurgery, Suite 614
Northwestern University
233 East Erie
Chicago, IL 60611

MITCHEL BERGER (Joan) 1997
Neurosurgery, Room 787
UCSF, Box 0112
505 Parnassus Avenue
San Francisco, CA 94143-0112

KEITH BLACK (Carol Bennett) 1995
Neurosurgery, Suite 490W
Cedars-Sinai Neurological Institute
8635 West Third Street
Los Angeles, CA 90048

PETER BLACK (Katharine) 1988
Department of Neurosurgery
Childrens Hospital
300 Longwood Avenue
Boston, MA 02115

LAWRENCE BORGES (Susan) 1993
Neurosurgery, White 1205
Massachusetts General Hospital
32 Fruit Street
Boston, MA 02114

CHARLES BRANCH, JR. (Lesa) 1996
Department of Neurosurgery
Wake Forest University
Medical Center Boulevard
Winston-Salem, NC 27157-1029

HENRY BREM (Rachel) 1996
Neurosurgery, Carnegie 466
Johns Hopkins Hospital
600 North Wolfe Street
Baltimore, MD 21287-0001

WILLIS BROWN, JR. (Ann) 1984
Division of Neurosurgery
Univ. of Texas Health Science Center
7703 Floyd Curl Drive
San Antonio, TX 78284-7843

DEREK BRUCE (Frances) 1984
Neurosurgery, Suite B308
7777 Forest Lane
Dallas, TX 75230-2505

KIM BURCHIEL (Debra) 1992
Neurosurgery, L-472
Oregon Health Sciences University
3181 S.W. Sam Jackson Park Road
Portland, OR 97201-3098

MARTIN CAMINS (Joan) 1995
Neurological Surgery, Suite T 1-C
205 East 68th Street
New York, NY 10021-5735

PETER CARMEL (Jacqueline Bello) 1991
Neurosurgery, Suite 7300
New Jersey Medical School
90 Bergen Street
Newark, NY 07103-2499

WILLIAM CHANDLER (Susan) 1989
2124D Taubman Health Center
University of Michigan
1500 East Medical Center Drive
Ann Arbor, MI 48109-0338

PAUL CHAPMAN (Tansy) 1983
Neurosurgery, GRB502
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114

PAUL COOPER (Leslie) 1995
Department of Neurosurgery
New York University Medical Center
550 First Avenue
New York, NY 10016-6481

REES COSGROVE (Karen) 1997
Neurosurgery, Suite 331
Massachusetts General Hospital
15 Parkman Street
Boston, MA 02114-2696

RALPH DACEY, JR. (Corinne Mears) 1990
Neurosurgery, CB 8057
Washington University
660 South Euclid
St. Louis, MO 63110

ARTHUR DAY (Dana) 1990
Department of Neurosurgery
University of Florida
P.O. Box 100265
Gainesville, FL 32610-0265

ROBERT DEMPSEY (Diane) 1996
Neurosurgery, H4/338
University of Wisconsin
600 Highland Avenue
Madison, WI 53792-0001

STEWART DUNSKER (Ellen) 1975
Suite 441
Mayfield Clinic & Spine Institute
2123 Auburn Avenue
Cincinnati, OH 45219-2970

MICHAEL EDWARDS (Linda) 1992
Neurosurgery, Suite 340
2800 L Street
Sacramento, CA 95816

HOWARD EISENBERG (Janet) 1985
Neurosurgery, S12D10A
University of Maryland
22 South Greene Street
Baltimore, MD 21201-1734

MEL EPSTEIN (Lynn) 1992
Suite 100
Neurosurgery Foundation, Inc.
55 Claverick Street
Providence, RI 02903

EUGENE FLAMM (Susan) 1979
Department of Neurosurgery
Beth Israel North
170 East End Avenue
New York, NY 10128

ALLAN FRIEDMAN (Elizabeth Bullitt) 1994
Division of Neurosurgery
Duke University Hospital
P.O. Box 3807
Durham, NC 27710

WILLIAM FRIEDMAN (Ransom) 1995
Department of Neurosurgery
University of Florida Health Sciences Center
P.O. Box 100265
Gainesville, FL 32610-0265

DANIEL FULTS, III (Carol) 1997
Department of Neurosurgery
University of Utah
50 North Medical Drive
Salt Lake City, UT 84132-0001

STEVEN GIANNOTTA (Sharon) 1992
Neurosurgery, Suite 5046
University of Southern California
1200 North State Street
Los Angeles, CA 90033-4525

ROBERT GRUBB, JR. (Julia) 1985
Neurosurgery, Campus Box 8057
Washington University
660 South Euclid Avenue
St. Louis, MO 63110-1010

JOSEPH HAHN (Andrea) 1993
Neurosurgery/S80
Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195-1004

STEPHEN HAINES (Jennifer Plambon) 1994
Neurosurgery, Suite 428
Medical Univ. of South Carolina
96 Jonathan Lucas Street
Charleston, SC 29425

ROBERTO HEROS (Deborah) 1985
Department of Neurosurgery
University of Miami
1501 NW 9th Avenue
Miami, FL 33136

CHARLES HODGE, JR. 1982
Department of Neurosurgery
State University Hospital
750 East Adams Street
Syracuse, NY 13210

L. NELSON (NICK) HOPKINS, III (Ann {Bonnie}) 1992
Department of Neurosurgery
State University of New York
3 Gates Circle
Buffalo, NY 14209-1194

PATRICK KELLY (Carol) 1992
Neurosurgery, Suite 8R
New York University
550 First Avenue
New York, NY 10016

GLENN KINDT (Charlotte) 1977
Neurosurgery, Box C307
University of Colorado
4200 East 9th Avenue
Denver, CO 80262-0001

DAVID KLINE (Nell) 1971
Department of Neurosurgery
Louisiana State Univ. Medical Center
1542 Tulane Avenue
New Orleans, LA 70112

DOUGLAS KONDZIOLKA (Susan) 1998
Neurosurgery, B-400
Univ. of Pittsburgh Medical Center
200 Lothrop Street
Pittsburgh, PA 15213-2582

EDWARD LAWS, JR. (Margaret) 1983
Department of Neurosurgery
University of Virginia
Box 212 Health Science Center
Charlottesville, VA 22908-0001

CHRISTOPHER LOFTUS (Sara) 1992
Neurosurgery, #206
University of Oklahoma
711 Stanton L. Young Boulevard
Oklahoma City, OK 73104

L. DADE LUNSFORD (Julianne) 1992
Neurosurgery, B-400
Univ. of Pittsburgh Medical Center
200 Lothrop Street
Pittsburgh, PA 15213-2582

NEIL MARTIN 1997
Department of Neurosurgery
UCLA Medical Center
Box 957039
Los Angeles, CA 90025-7039

ROBERT MARTUZA (Jill) 1989
Neurosurgery/PHC 1
Georgetown University Medical Center
3800 Reservoir Road NW
Washington, DC 20007-2197

ROBERT MAXWELL (Karen) 1992
Neurosurgery, Box 96
University of Minnesota
420 Delaware Street SE
Minneapolis, MN 55455-0374

MARC MAYBERG (Terry) 1995
Neurosurgery/S80
The Cleveland Clinic
9500 Euclid Avenue
Cleveland, OH 44195

J. GORDON MCCOMB (Rhoda) 1998
Neurosurgery, #906
1300 North Vermont Avenue
Los Angeles, CA 90027

PAUL MCCORMICK (Doris) 1998
Department of Neurosurgery
Columbia Presbyterian Medical
710 West 168th Street
New York, NY 10032

J. MICHAEL MCWHORTER (Barbara) 1989
Carolina Neurosurgical Associates
2810 North Maplewood Avenue
Winston-Salem, NC 27103-4151

FREDRIC MEYER (Irene Meissner) 1995
Department of Neurologic Surgery
Mayo Clinic
200 First Street SW
Rochester, MN 55905

RICHARD MORAWETZ (Mary Jean) 1990
Neurosurgery/MEB 512
University of Alabama
1600 Seventh Avenue South
Birmingham, AL 35294-3295

PAUL NELSON (Teresa) 1991
Neurosurgery, Emerson #139
Indiana University
545 Barnhill Drive
Indianapolis, IN 46202-5124

GEORGE OJEMANN (Dr. Linda M.). 1975
Neurological Surgery, Box 359924
University of Washington
1959 N.E. Pacific Street
Seattle, WA 98195-9924

EDWARD OLDFIELD (Susan) 1975/1997
Building 10, Room #5D37
National Institutes of Health
10 Center Drive
Bethesda, MD 20892-1414

ANDRE OLIVIER (Nicole) 1989
Division of Neurosurgery, #109
Montreal Neurological Institute
3801 University Street
Montreal, Quebec H3A 2B4
CANADA

TAE SUNG PARK (Hyun Sook Kim) 1996
Neurosurgery, Suite 4520
St. Louis Childrenís Hospital
One Childrenís Place
St. Louis, MO 63110

DAVID G. PIEPGRAS (Jane) 1987
Department of Neurologic Surgery
Mayo Clinic
200 First Street SW
Rochester, MN 55905

LAWRENCE PITTS (Mary) 1997
Department of Neurosurgery
Box 0112, Room M-780C
UCSF Medical Center
San Francisco, CA 94143-0112

KALMON POST (Linda) 1995
Neurosurgery, Box 1136
Mount Sinai Medical Center
1 Gustave L. Levy Place
New York, NY 10029-6574

DONALD QUEST (Ilona) 1986
Department of Neurological Surgery
The Neurological Institute
710 West 168th Street
New York, NY 10032

COREY RAFFEL (Kathy) 1998
Department of Neurologic Surgery
Mayo Clinic
200 First Street SW
Rochester, MN 55905

BERT RATCHESON (Peggy Steiner) 1986
Department of Neurosurgery
University Hospitals of Cleveland
11100 Euclid Avenue
Cleveland, OH 44106-5000

J. CHARLES RICH, JR. (Jasmine) 1987
Neurosurgery, Suite 111
Neurosurgical Associates, Inc.
370 Ninth Avenue
Salt Lake City, UT 84103-2677

DAVID ROBERTS (Kathryn) 1996
Section of Neurosurgery
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03758-0001

JON ROBERTSON (Carol Ann) 1992
Neurosurgery, Suite 600
920 Madison Avenue
Memphis, TN 38103

ROBERT ROSENWASSER (Deborah August) 1996
Neurosurgery, Suite 650
Jefferson Faculty Foundation
834 Walnut Street
Philadelphia, PA 19107-5102

JAMES RUTKA (Mari) 1996
Neurosurgery, Suite 1502
The Hospital for Sick Children
555 University Avenue
Toronto, Ontario M5G 1X8
CANADA

DUKE SAMSON (Patricia) 1994
Department of Neurosurgery
Univ. of Texas, Southwestern Med. Center
5323 Harry Hines Boulevard
Dallas, TX 75235-8855

R. MICHAEL SCOTT (Susan) 1991
Neurosurgery, Bader 319
Childrenís Hospital
300 Longwood Avenue
Boston, MA 02115-5724

WARREN SELMAN (Diana) 1995
Neurosurgery, HHS 5042
University Hospitals of Cleveland
11100 Euclid Avenue
Cleveland, OH 44106

CHRISTOPHER SHIELDS (Deborah) 1993
Neurosurgery, Suite 1102
University of Louisville
210 East Gray Street
Louisville, KY 40202

FREDERICK SIMEONE 1981
Department of Neurosurgery
Pennsylvania Hospital
909 Walnut Street
Philadelphia, PA 19107

ROBERT SOLOMON (Barbara) 1996
Neurological Institute of New York
710 West 168th Street
New York, NY 10032-2603

VOLKER SONNTAG (Lynne) 1995
Division of Neurological Surgery
Barrow Neurological Institute
2910 North Third Avenue
Phoenix, AZ 85013

DENNIS SPENCER (Susan) 1989
Neurological Surgery, Box 208082
Yale University
333 Cedar Street
New Haven, CT 06520-8082

ROBERT SPETZLER (Nancy) 1997
Barrow Neurosurgical Assoc., Ltd.
2910 North Third Avenue
Phoenix, AZ 85013-4496

JOHN TEW, JR. (Susan) 1971
Department of Neurosurgery
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0515

SUZIE TINDALL 1990
Department of Neurosurgery
Emory University
1365 Clifton Road NE
Atlanta, GA 30322-1013

RUSSELL TRAVIS 1994
Neurosurgical Associates, #485B
1401 Harrodsburg Road
Lexington, KY 40504-3700

HARRY VAN LOVEREN (Judy) 1995
Neurosurgery, Suite 110
3219 Clifton Avenue
Cincinnati, OH 45220-3027

RAND VOORHIES (Terry) 1996
Department of Neurosurgery
Ochsner Clinic
1514 Jefferson Highway
New Orleans, LA 70121-2483

BRYCE WEIR (Mary Lou) 1984
Section of Neurosurgery, MC 3026
University of Chicago
5841 South Maryland Avenue
Chicago, IL 60637

MARTIN WEISS (Debby) 1981
Neurosurgery, Box 766
USC Medical Center
1200 North State Street
Los Angeles, CA 90033

H. RICHARD WINN (Debbie) 1993
Neurosurgery, Box 359924
University of Washington
700 Ninth Avenue
Seattle, WA 98195-9924

FREMONT PHILIP WIRTH 1993
4 Jackson Boulevard
Savannah, GA 31405-5810

ALLEN WYLER (Lily) 1990
Epilepsy Center, Box 14999
Swedish Medical Center
747 Summit
Seattle, WA 98114-0999

A. BYRON YOUNG (Judy) 1989
Neurosurgery, MS101
University of Kentucky
800 Rose Street
Lexington, KY 40536-0084

RONALD YOUNG 1986
Northwest Gamma Knife Center, #G-5
1560 North 115th Street
Seattle, WA 98133

INACTIVE

Elected

ROBERT CROWELL (Mary) 1990
1801 Elm Street
Box 168
Pittsfield, MA 01201

RICHARD KRAMER (Mollie) 1978
Duke University Medical Center
Box 3255
Durham, NC 27710

SENIOR CORRESPONDING

Elected

R. LEIGH ATKINSON (Noela) 1989
Alexandra, Suite 9, 2nd Floor
201 Wickham Terrace
Brisbane, Queensland 4000
AUSTRALIA

ARMANDO BASSO (Milva) 1996
Ayacucho 1342
Buenos Aires, Cap. Fed. 1111
ARGENTINA

FERNANDO CABIESES 1966
Apartado 5254
Peruano De Formento Educativo
Av. Arenales 371, of. 501
Lima
PERU

LUC CALLIAUW (Dora) 1988
Neurosurgery, Akademisch Ziekenhus
University of Ghent
De Pintelaan, 185
9000 Ghent
BELGIUM

JUAN CARLOS CHRISTENSEN (Diana Poli) 1970
Jose C. Paz 234
Acassuso (1641)
Buenos Aires
ARGENTIA

GUISEPPE DALLE ORE (Guisi) 1970
Via Rovereto N. 22
Verona, 37126
ITALY

JACQUES DEVILLIERS (Jeanne Marie Erica) 1986
Department of Neurosurgery
University of Cape Town
Observatory 7925
Cape Town 7
SOUTH AFRICA

HANS ERICH DIEMATH (Dr. Karin) 1970
Department of Neurosurgery
Landesnervenklinik
Ignaz Harrer-Strasse 79
Salzburg, A-5020
AUSTRIA

HERMANN DIETZ (Elfrun) 1970
An Der Trift 10 B
Hannover, 30559
GERMANY

F. JOHN GILLINGHAM (Judy) 1962
Easter Park House
Easter Park Drive
Edinburgh, EH4 6SN
SCOTLAND

JAIME G. GOMEZ (Lucy) 1975
Suite 2-549
7040 West Palmetto Park Road
Boca Raton, FL 33433

SALVADOR GONZALEZ-CORNEJO (Rosa) 1982
Av. Chapultepec Sua 130-204
Guadalajara, Jal. 44630
MEXICO

ERNST H. GROTE (Juliana) 1984
Department of Neurosurgery
University Kliniks Schnarrenberg
Hoppe Seyler-Str. 3
72076 Tubingen
GERMANY

HAJIME HANDA (Hiroko) 1985
Takeda General Hospital
26-1 Moriminami-cho, Ishida
Fushimi-ku
Kyoto, 601-1495
JAPAN

JOHN HANKINSON (Nicole) 1973
Westacres, Woolsington Hall
Newcastle Upon Tyne, England NE13 8DG
UNITED KINGDOM

FABIAN ISAMAT (Maria Victoria {Marivi}) 1989
Clinica Sagrade Familia
Neurogrup
Torras y Pujalt, 1
08022 Barcelona
SPAIN

SHOZO ISHII (Akiko) 1975
Department of Neurosurgery
Juntendo Medical College
2-1-1 Hongo, Bunkyo-ku
Tokyo 113-8421
JAPAN

HANS-PETER JENSEN 1980
Karolinenweg 23
Kiel, 24105
GERMANY

KATSUTOSHI KITAMURA (Yoshiko) 1970
Neurosurgery Neurologic Institute
Kyushu University
3-1-1 Maidashi, Higashi-ku
Fukuoka, 812-8582
JAPAN

SHIGEAKI KOBAYASHI (Hideko) 1998
Department of Neurosurgery
Shinshu University
Matsumoto 390-8621
JAPAN

LAURI LAITINEN (Kerstin) 1972
Dano, FI-22340
Geta
FINLAND

RUEDIGER LORENZ 1998
Department of Neurosurgery
J. W. Goethe Univ. Clinic
Schleusenweg 2-16
Frankfurt, Main 60528
GERMANY

RAUL MARINO, JR (Angela) 1977
R. Maestro Cardim 808/814
Sao Paulo, SP 01323-001
BRAZIL

JORGE S. MENDEZ (Soledad) 1997
Marcoleta 377
Santiago
CHILE

B. RAMAMURTHI (Indira) 1973
Voluntary Health Services
Taramani
Chennai 600-113
INDIA

HANS-J. REULEN (Ute) 1998
Neurosurgical Clinic
Klinikum Grosshadern
Marchioninistrasse 15
Munich 81377
GERMANY

MADJID SAMII (Mahschi) 1996
Neurosurgery Clinic
Nordstadt Hospital
Haltenhoffstrasse 41
Hannover 30167
GERMANY

KURT-FRIEDRICH SCHURMANN 1978
Am Eselsweg 29
D-6500 Mainz 1
GERMANY

CHARAS SUWANWELA 1972
Chulalongkorn Hospital
Medical School
Bangkok
THAILAND

LINDSAY SYMON (Pauline) 1982
Department of Neurosurgery
The National Hospital
Queen Square
London, England WC 1
UNITED KINGDOM

KINTOMO TAKAKURA (Tsuneko) 1988
Tokyo Womenís Medical University
8-1 Kawadacho, Shinjukuku
Tokyo, 162-8666
JAPAN

KJELD VAERNET 1970
Gardes Alle 7, 4 TV
Hellerup, 2900
DENMARK

SYDNEY ERIC WATKINS (Susan) 1975
Royal London Hospital
Whitechapel
London, England E1 1BB
UNITED KINGDOM

M. GAZI YASARGIL (Dianne) 1975
Neurosurgery, Slot 507
University of Arkansas
4301 West Markham
Little Rock, AR 72205-7199

CORRESPONDING

Elected

H. ALAN CROCKARD (Caroline) 1992
Department of Surgical Neurology
National Hospital
Queen Square
London, England 1N 3BG
UNITED KINGDOM

NOEL G. DAN (Adrienne) 1989
Specialist Medical Center, Suite 302
235-285 New South Head Road
Edgecliff, 2027
Sydney, N.S.W.
AUSTRALIA

NICOLAS DE TRIBOLET (Veronique) 1995
Service de Neurochirurgie
Hopital Cantonal de Geneve
Rue Micheli-du-Crest 24
1211 Geneve 14
SWITZERLAND

VINKO DOLENC 1988
Department of Neurosurgery
University Hospital Center
Zaloska 7
1525 Ljubljana
SLOVENIA

RUDOLPH FAHLBUSCH (Hanna) 1991
Neurochirurgische Klinik
Universitat Erlangen-Nurnberg
Schwabachanlage 6
Erlangen, 91054
GERMANY

DAE HEE HAN (Sung Soon Cho) 1991
#28 Yongon-dong
Chongno-Gu
Seoul National Univ. Hospital
Seoul, 110-744
SOUTH KOREA

TAKESHI KAWASE (Mieko) 1997
Department of Neurosurgery
Kelo University
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582
JAPAN

ANDREW KAYE (Judith) 1996
Department of Surgery
Royal Melbourne Hospital
Parkville 3050
Melbourne, Victoria
AUSTRALIA

HARUHIKO KIKUCHI 1993
Department of Neurosurgery
Kyoto University
54, Kawahara-cho, Shogoin
Sakyo-ku, Kyoto City, Kyoto 607
JAPAN

DAVID THOMAS (Hazel) 1995
Institute of Neurology
Queen Square
London, England WC1N 3BG
UNITED KINGDOM

DECEASED MEMBERS

	Elected	Deceased
JAMES R. ATKINSON Phoenix, Arizona (Active)	1970	1978
PERCIVAL BAILEY Evanston, Illinois (Honorary)	1960	1973
GEORGE BAKER Litchfield Park, Arizona (Senior)	1940	1993
H. THOMAS BALLANTINE, JR. Boston, Massachusetts (Senior)	1951	1996
WILLIAM F. BESWICK Buffalo, New York (Active)	1959	1971
EDWIN B. BOLDREY San Francisco, California (Senior)	1941	1988
E. HARRY BOTTERELL Kingston, Ontario, CANADA (Senior)	1938	1997
SPENCER BRADEN Cleveland, Ohio (Active)	Founder	1969
F. KEITH BRADFORD Houston, Texas (Active)	1938	1971
JEAN BRIHAYE Bruxelles, BELGIUM (Senior Corresponding)	1975	1999

KARL-AUGUST BUSHE 1972 1999
Wurzburg, GERMANY
(Senior Corresponding)

HOWARD BROWN 1939 1990
San Francisco, California
(Senior)

JUAN CARDENAS 1966 1996
Mexico City, MEXICO
(Senior Corresponding)

GALE CLARK 1970 1996
Oakland, California
(Senior)

DONALD COBURN 1938 1988
Wilmington, Delaware
(Senior)

WINCHELL McK. CRAIG 1942 1960
Rochester, Minnesota
(Honorary)

EDWARD DAVIS 1949 1988
Portland, Oregon
(Senior)

PEARDON DONAGHY 1970 1991
Burlington, Vermont
(Senior)

CHARLES DRAKE 1958 1998
London, Ontario, CANADA
(Senior)

FRANCIS ECHLIN 1944 1988
New Poaltz, New York
(Senior)

DEAN ECHOLS ..... Founder 1991
New Orleans, Louisiana
(Senior)

GEORGE EHNI 1964 1986
Houston, Texas
(Senior)

ARTHUR ELVIDGE 1939 1985
Montreal, Quebec, CANADA
(Senior)

THEODORE ERICKSON 1940 1986
Madison, Wisconsin
(Senior)

JOSEPH EVANS ..... Founder 1985
Kensington, Maryland
(Senior)

JOHN FRENCH 1951 1989
Los Angeles, California
(Senior)

JAMES GALBRAITH 1947 1997
Birmingham, Alabama
(Senior)

EVERETT GRANTHAM 1942 1997
Louisville, Kentucky
(Senior)

JOHN GREEN 1953 1990
Phoenix, Arizona
(Senior)

JAMES GREENWOOD, JR. 1952 1992
Houston, Texas
(Senior)

WESLEY GUSTAFSON 1942 1975
Jensen Beach, Florida
(Senior)

WALLACE HAMBY 1941 1999
Pompano Beach, Florida
(Senior)

HANNIBAL HAMLIN 1949 1982
Providence, Rhode Island
(Senior)

JOHN HANBERY 1959 1996
Palo Alto, California
(Senior)

JESS HERRMANN 1938 1994
Oklahoma City, Oklahoma
(Senior)

HENRY HEYL 1951 1975
Hanover, New Hampshire
(Senior)

WILLIAM HUNT 1970 1999
Columbus, Ohio
(Senior)

OLAN HYNDMAN 1942 1966
Iowa City, Iowa
(Senior)

KENNETH JAMIESON 1970 1976
Brisbane, AUSTRALIA
(Corresponding)

SIR GEOFFREY JEFFERSON 1951 1961
Manchester, ENGLAND
(Honorary)

RICHARD JOHNSON 1974 1997
Cheadle Hulme, ENGLAND
(Senior Corresponding)

WILLIAM KEITH ..... Founder 1987
Toronto, CANADA
(Senior)

HUGO KRAYENBUHL 1974 1985
Zurich, SWITZERLAND
(Honorary)

KRISTIAN KRISTIANSEN 1967 1993
Oslo, Norway
(Senior Corresponding)

WALPOLE LEWIN 1973 1980
Cambridge, ENGLAND
(Corresponding)

HERBERT LOURIE 1965 1987
Syracuse, New York
(Senior)

WILLEM LUYENDIJK 1973 1995
Oegstgeest, NETHERLANDS
(Senior Corresponding)

M. STEPHEN MAHALEY 1972 1992
Birmingham, Alabama
(Active)

GEORGE MALTBY 1942 1988
Scarsborough, Maine
(Senior)

FRANK MARGUTH 1978 1991
Munich, GERMANY
(Senior Corresponding)

DONALD MATSON 1950 1969
Boston, Massachusetts
(Active)

FRANK MAYFIELD ..... Founder 1991
Cincinnati, Ohio
(Senior)

AUGUSTUS McCRAVEY 1944 1990
Chattanooga, Tennessee
(Senior)

KENNETH McKENZIE 1960 1964
Toronto, CANADA
(Honorary)

WILLIAM MEACHAM 1952 1999
Nashville, Tennessee
(Senior)

JAMES MEREDITH 1946 1962
Richmond, Virginia
(Active)

J. DOUGLAS MILLER 1988 1995
Edinburgh, SCOTLAND
(Corresponding)

W. JASON MIXTER 1951 1968
Woods Hole, Massachusetts
(Honorary)

EDMUND MORRISSEY 1941 1986
San Francisco, California
(Senior)

FRANCIS MURPHEY ..... Founder 1994
Naples, Florida
(Senior)

GOSTA NORLEN 1973 1985
Goteborg, SWEDEN
(Honorary)

FRANK NULSEN 1956 1994
Naples, Florida
(Senior)

SIXTO OBRADOR 1973 1978
Madrid, SPAIN
(Honorary)

PIETRO PAOLETTI 1989 1991
Milan, ITALY
(Corresponding)

HANS-WERNER PIA 1978 1986
Giessen, WEST GERMANY
(Corresponding)

WILDER PENFIELD 1960 1976
Montreal, CANADA
(Honorary)

HELMUT PENZHOLZ 1978 1985
Heidelberg, WEST GERMANY
(Corresponding)

ROBERT PUDENZ 1943 1998
South Pasadena, California
(Senior)

BRONSON RAY 1992 1993
New York, New York
(Honorary)

DAVID REEVES 1939 1970
Santa Barbara, California
(Active)

DAVID REYNOLDS 1964 1978
Tampa, Florida
(Active)

R. C. L. ROBERTSON 1946 1985
Houston, Texas
(Senior)

STEWART ROWE 1938 1984
Pittsburgh, Pennsylvania
(Senior)

RICHARD SCHNEIDER 1970 1986
Ann Arbor, Michigan
(Senior)

HENRY SCHWARTZ 1942 1998
St. Louis, Missouri
(Senior)

WILLIAM SCOVILLE 1944 1984
Hartford, Connecticut
(Senior)

R. EUSTACE SEMMES 1955 1982
Memphis, Tennessee
(Honorary)

SAMUEL SNODGRASS 1939 1975
Galveston, Texas
(Senior)

GLEN SPURLING 1942 1968
LaJolla, California
(Honorary)

C. WILLIAM STEWART 1948 1948
Montreal, CANADA
(Corresponding)

THORALF SUNDT, JR. 1971 1992
Rochester, Minnesota
(Active)

KENICHIRO SUGITA 1988 1994
Nagoya, Japan
(Senior Corresponding)

HENDRIK SVIEN 1957 1972
Rochester, Minnesota
(Active)

HOMER SWANSON 1949 1987
Atlanta, Georgia
(Senior)

ALFRED UIHLEIN 1950 1990
Rochester, Minnesota
(Senior)

A. EARL WALKER 1938 1995
Albuquerque, New Mexico
(Senior)

ARTHUR WARD, JR. 1953 1997
Seattle, Washington
(Senior)

THOMAS WEAVER, JR. 1943 1985
Dayton, Ohio
(Senior)

W. KEASLEY WELCH 1957 1996
Waban, Massachusetts
(Senior)

BENJAMIN WHITCOMB 1947 1998
Surrey, Maine
(Senior)

BARNES WOODHALL 1941 1985
Durham, North Carolina
(Senior)

FRANK WRENN 1973 1990
Greenville, South Carolina
(Senior)

NOTES:

THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

62nd Annual Meeting

October 11-14, 2000

THE BROADMOR

Colorado Springs, Colorado

The Broadmor, located in Colorado Springs at the foot of the Rockies, provides an environment of unparalleled beauty and luxury. One of the few resorts in the country to have earned the Mobil Five Star and the AAA Five Diamond ratings every year since the awards were established. The Broadmoor is proud to provide guests with the finest in accommodations and services.

Recreational Activities include: Golf, Tennis, full service Spa and Fitness Center, Biking, Walking, Running Trails, Horse and Carriages, Ballooning, Fly Fishing Trips and many more nearby Attractions.

MARK YOUR CALENDARS NOW!